<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>SurgeryProcedure.info &#187; Search Results  &#187;  mesh rejection</title>
	<atom:link href="http://surgeryprocedure.info/?s=mesh%20rejection&#038;feed=rss2" rel="self" type="application/rss+xml" />
	<link>http://surgeryprocedure.info</link>
	<description>Questions and Answers About Surgery From Diagnosis to Recovery</description>
	<lastBuildDate>Fri, 07 Aug 2009 14:58:08 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Queries 5</title>
		<link>http://surgeryprocedure.info/top-search/queries-5</link>
		<comments>http://surgeryprocedure.info/top-search/queries-5#comments</comments>
		<pubDate>Mon, 21 Sep 2009 06:21:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/top-search/queries-5</guid>
		<description><![CDATA[

sengstaken blakemore tube
hernia mesh rejection symptoms
fissurotomy
lasix sandwich
anal+fissurotomy
sengstaken blakemore
empyema necessitans
sengstaken-blakemore
Space of Bogros Bhernia
anal fissurotomy
esophageal varices
shalyajanya nadi vrana
penetrating neck carotid artery
pilonoidal sinus
gatorade spleen
urinary+tract+surgery
CHRONIC INTESTIONAL PSEUDOOBSTRUCTION
rocky davis incision
urinary tract trauma
caput medusae dilated veins
spleen injury with blood behind heart
bleeding caput medusa
hernia mesh neuroma
neuroma+hernia
mesh rejection
emphysema necessitans
Infant Testicle
blakemore+tube
spleen injury


]]></description>
			<content:encoded><![CDATA[<p><span id="more-566"></span>
<ul>
<li><a href="http://surgeryprocedure.info/search/sengstaken-blakemore+tube">sengstaken blakemore tube</a></li>
<li><a href="http://surgeryprocedure.info/search/hernia+mesh+rejection+symptoms">hernia mesh rejection symptoms</a></li>
<li><a href="http://surgeryprocedure.info/search/fissurotomy">fissurotomy</a></li>
<li><a href="http://surgeryprocedure.info/search/lasix+sandwich">lasix sandwich</a></li>
<li><a href="http://surgeryprocedure.info/search/anal+fissurotomy">anal+fissurotomy</a></li>
<li><a href="http://surgeryprocedure.info/search/sengstaken+blakemore">sengstaken blakemore</a></li>
<li><a href="http://surgeryprocedure.info/search/empyema+necessitans">empyema necessitans</a></li>
<li><a href="http://surgeryprocedure.info/search/sengstaken-blakemore">sengstaken-blakemore</a></li>
<li><a href="http://surgeryprocedure.info/search/Space+of+Bogros+hernia">Space of Bogros Bhernia</a></li>
<li><a href="http://surgeryprocedure.info/search/anal+fissurotomy">anal fissurotomy</a></li>
<li><a href="http://surgeryprocedure.info/search/esophageal+varices">esophageal varices</a></li>
<li><a href="http://surgeryprocedure.info/search/shalyajanya+nadi+vrana">shalyajanya nadi vrana</a></li>
<li><a href="http://surgeryprocedure.info/search/penetrating+neck+carotid+artery">penetrating neck carotid artery</a></li>
<li><a href="http://surgeryprocedure.info/search/pilonoidal+sinus">pilonoidal sinus</a></li>
<li><a href="http://surgeryprocedure.info/search/gatorade+spleen">gatorade spleen</a></li>
<li><a href="http://surgeryprocedure.info/search/urinary+tract+surgery">urinary+tract+surgery</a></li>
<li><a href="http://surgeryprocedure.info/search/CHRONIC+INTESTIONAL+PSEUDOOBSTRUCTION">CHRONIC INTESTIONAL PSEUDOOBSTRUCTION</a></li>
<li><a href="http://surgeryprocedure.info/search/rocky+davis+incision">rocky davis incision</a></li>
<li><a href="http://surgeryprocedure.info/search/urinary+tract+trauma">urinary tract trauma</a></li>
<li><a href="http://surgeryprocedure.info/search/caput+medusae+dilated+veins">caput medusae dilated veins</a></li>
<li><a href="http://surgeryprocedure.info/search/spleen+injury+with+blood+behind+heart">spleen injury with blood behind heart</a></li>
<li><a href="http://surgeryprocedure.info/search/bleeding+caput+medusa">bleeding caput medusa</a></li>
<li><a href="http://surgeryprocedure.info/search/hernia+mesh+neuroma">hernia mesh neuroma</a></li>
<li><a href="http://surgeryprocedure.info/search/neuroma+hernia">neuroma+hernia</a></li>
<li><a href="http://surgeryprocedure.info/search/mesh+rejection">mesh rejection</a></li>
<li><a href="http://surgeryprocedure.info/search/emphysema+necessitans">emphysema necessitans</a></li>
<li><a href="http://surgeryprocedure.info/search/Infant+Testicle">Infant Testicle</a></li>
<li><a href="http://surgeryprocedure.info/search/blakemore+tube">blakemore+tube</a></li>
<li><a href="http://surgeryprocedure.info/search/spleen+injury">spleen injury</a></li>
</ul>
<p><!--more--></p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/top-search/queries-5/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Queries 3</title>
		<link>http://surgeryprocedure.info/top-search/queries-3</link>
		<comments>http://surgeryprocedure.info/top-search/queries-3#comments</comments>
		<pubDate>Fri, 14 Aug 2009 18:10:27 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?page_id=562</guid>
		<description><![CDATA[

sengstaken blakemore tube
blakemore tube
post splenectomy leukocytosis
esophageal varices
abdominal trauma hematoma,calcium nodule
dextrose
colon benign obstruction web
forum for people with imperforate anus
barium enema in neonates
disease of anorectal
empyema necessitans
penetrating neck trauma management asymptomatic
open abdominal surgery in cirrhotic patients
what is stump pressure?
suturing facial laceration
surgically correctable causes of hypertension
solution dakin sinus pilonidale
rejection of hernia mesh neuroma formation
albumin and Lasix sandwich


]]></description>
			<content:encoded><![CDATA[<p><span id="more-562"></span>
<ul>
<li><a href="http://surgeryprocedure.info/search/sengstaken+blakemore+tube">sengstaken blakemore tube</a></li>
<li><a href="http://surgeryprocedure.info/search/blakemore+tube">blakemore tube</a></li>
<li><a href="http://surgeryprocedure.info/search/post+splenectomy+leukocytosis">post splenectomy leukocytosis</a></li>
<li><a href="http://surgeryprocedure.info/search/esophageal+varices">esophageal varices</a></li>
<li><a href="http://surgeryprocedure.info/search/abdominal+trauma+hematoma+calcium+nodule">abdominal trauma hematoma,calcium nodule</a></li>
<li><a href="http://surgeryprocedure.info/search/dextrose">dextrose</a></li>
<li><a href="http://surgeryprocedure.info/search/colon+benign+obstruction+web">colon benign obstruction web</a></li>
<li><a href="http://surgeryprocedure.info/search/forum+for+people+with+imperforate+anus">forum for people with imperforate anus</a></li>
<li><a href="http://surgeryprocedure.info/search/barium+enema+in+neonates">barium enema in neonates</a></li>
<li><a href="http://surgeryprocedure.info/search/disease+of+anorectal">disease of anorectal</a></li>
<li><a href="http://surgeryprocedure.info/search/empyema+necessitans">empyema necessitans</a></li>
<li><a href="http://surgeryprocedure.info/search/penetrating+neck+trauma+management+asymptomatic">penetrating neck trauma management asymptomatic</a></li>
<li><a href="http://surgeryprocedure.info/search/open+abdominal+surgery+in+cirrhotic+patients">open abdominal surgery in cirrhotic patients</a></li>
<li><a href="http://surgeryprocedure.info/search/what+is+stump+pressure?">what is stump pressure?</a></li>
<li><a href="http://surgeryprocedure.info/search/suturing+facial+laceration">suturing facial laceration</a></li>
<li><a href="http://surgeryprocedure.info/search/surgically+correctable+causes+of+hypertension">surgically correctable causes of hypertension</a></li>
<li><a href="http://surgeryprocedure.info/search/solution+dakin+sinus+pilonidale">solution dakin sinus pilonidale</a></li>
<li><a href="http://surgeryprocedure.info/search/rejection+of+hernia+mesh+neuroma+formation">rejection of hernia mesh neuroma formation</a></li>
<li><a href="http://surgeryprocedure.info/search/albumin+and+Lasix+sandwich">albumin and Lasix sandwich</a></ul>
</li>
<p><!--more--></p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/top-search/queries-3/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Inguinal Hernia. Controversies</title>
		<link>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia-controversies</link>
		<comments>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia-controversies#comments</comments>
		<pubDate>Thu, 09 Jul 2009 08:12:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ABDOMINAL SURGERY]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=290</guid>
		<description><![CDATA[CONTROVERSIES
36. What are some of the anatomic issues related to inguinal hernias?
 	Show answer
At issue is the iliopubic tract, which is central to the Anson/McVay anatomic description of the inguinal area and featured in the McVay Cooper&#8217;s ligament repair. Although the McVay repair is used in England, the iliopubic tract is not referred to or [...]]]></description>
			<content:encoded><![CDATA[<p><strong>CONTROVERSIES</strong></p>
<blockquote><p><strong>36. What are some of the anatomic issues related to inguinal hernias?</strong></p></blockquote>
<p> 	Show answer<br />
At issue is the iliopubic tract, which is central to the Anson/McVay anatomic description of the inguinal area and featured in the McVay Cooper&#8217;s ligament repair. Although the McVay repair is used in England, the iliopubic tract is not referred to or described in English anatomic texts.<br />
<span id="more-290"></span><br />
The term conjoined tendon, although commonly used, is considered by many to be anatomically inaccurate and misleading. The internal oblique and transversus abdominis muscles that make up the conjoined tendon are obvious and can be used surgically either alone or together. The tendinous edge of the transversus abdominis muscle and the tendinous edge of the internal oblique muscle start at their insertion on the pubic tubercle and course laterally and superiorly to the medial edge of the internal ring. At this point, the tendinous elements diminish, leaving only muscle tissues, and continue laterally and superiorly to their origins.<br />
Whether the lacunar ligament or the iliopubic tract defines the medial border of the femoral canal is controversial. The compromise position is that the iliopubic tract is the border whereas in the normal unstretched state, the lacunar ligament (Gimbernat&#8217;s ligament) is the border in the presence of hernia (stretched state). At surgery it is enough to say that a palpable, visible curved ligament is present and used in some femoral repairs.</p>
<blockquote><p><strong>37. What are some surgical issues in the repair of inguinal hernias?</strong></p></blockquote>
<p> 	Show answer </p>
<p>The controversy over implanting mesh, as in the Lichtenstein repair, has been resolved in favor of mesh. Another controversy concerns the use of the laparoscope for hernia repair. A further issue is intra-abdominal or preperitoneal placement of mesh. At present, most surgeons accept laparoscopic repair as an alternative for preperitoneal hernia repair. The indications for a preperitoneal approach to hernia repair are still being defined, although the preperitoneal approach is acceptable for repair of recurrent hernia and unusually large or difficult hernias. The preperitoneal approach is used with increasing frequency for repair of femoral hernias. The repair should be appropriate to the circumstance of the hernia. Thus, hernia location and size as well as the patient&#8217;s age, general condition, and recurrence status should be factored into the strategy of repair.</p>
<p><strong><br />
References</strong><br />
BIBLIOGRAPHY<br />
1. Avisse C, Delattre JF, Flament JB: The inguinal rings. Surg Clin North Am 80:49-69, 2000.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10685144&#038;dopt=Abstract"> Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10685144">Similar articles</a><br />
2. Avisse C, Delattre JF, Flament JB: The inguinofemoral area from a laparoscopic standpoint. History, anatomy, and surgical applications. Surg Clin North Am 80:35-48, 2000. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10685143&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10685143">Similar articles</a><br />
3. Bendavid R, Howarth D: Transversalis fascia rediscovered. Surg Clin North Am 80:25-33, 2000. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10685142&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10685142">Similar articles</a><br />
4. Collaboration EH: Laparoscopic compared with open methods of groin hernia repair: Systematic review of randomized controlled trials. Br J Surg 87:860-867, 2000. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10931019&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10931019">Similar articles</a><a href="http://dx.doi.org/10.1046/j.1365-2168.2000.01540.x"> Full article</a><br />
5. Collaboration EH: Mesh compared with non-mesh methods of open groin hernia repair. Systematic review of randomized controlled trials. Br J Surg 87:854-859, 2000.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10931018&#038;dopt=Abstract"> Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10931018">Similar articles</a> <a href="http://dx.doi.org/10.1046/j.1365-2168.2000.01539.x">Full article</a></p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia-controversies/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Inguinal Hernia</title>
		<link>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia</link>
		<comments>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia#comments</comments>
		<pubDate>Thu, 09 Jul 2009 07:46:44 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ABDOMINAL SURGERY]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=285</guid>
		<description><![CDATA[56 INGUINAL HERNIA
Gregory P. Victorino M.D., Jyoti Arya M.D., James Bascom M.D.
1. &#8220;Groin&#8221; hernia refers to which three hernias? 	
Show answer
Direct and indirect inguinal hernias and femoral hernias.

2. Francois Poupart, a French surgeon and anatomist (1616-1708), described a ligament that bears his name. What is the anatomic name of the Poupart ligament?
 	Show answer
Inguinal ligament, [...]]]></description>
			<content:encoded><![CDATA[<p><strong>56 INGUINAL HERNIA<br />
Gregory P. Victorino M.D., Jyoti Arya M.D., James Bascom M.D.</strong></p>
<blockquote><p><strong>1. &#8220;Groin&#8221; hernia refers to which three hernias? </strong>	</p></blockquote>
<p>Show answer<br />
Direct and indirect inguinal hernias and femoral hernias.<br />
<span id="more-285"></span></p>
<blockquote><p><strong>2. Francois Poupart, a French surgeon and anatomist (1616-1708), described a ligament that bears his name. What is the anatomic name of the Poupart ligament?</strong></p></blockquote>
<p> 	Show answer<br />
Inguinal ligament, which is a key element in most groin hernia repair.</p>
<blockquote><p><strong>3. Franz K. Hesselbach, a German surgeon and anatomist (1759-1816), described a triangle that is the common site of direct hernias. What are the anatomic margins of Hesselbach&#8217;s triangle?</strong></p></blockquote>
<p> 	Show answer<br />
The triangle is defined inferiorly by the inguinal ligament, superiorly by the inferior epigastric vessels, and medially by the rectus fascia. The transversalis fascia forms the floor of the triangle. The original description used Cooper&#8217;s ligament as the inferior limit but because of the common use of the anterior approach to hernias, the more apparent inguinal ligament was substituted as the inferior limit of the triangle. With the increasing use of preperitoneal approaches to hernia repair, Cooper&#8217;s ligament is again much more apparent and useful as an anatomic touchstone.</p>
<blockquote><p><strong>4. Sir Astley Paston Cooper, an English surgeon and anatomist (1768-1841), described a ligament bearing his name. What is the anatomic name for the ligament and the proper name of Cooper&#8217;s ligament repair? </strong>	</p></blockquote>
<p>Show answer<br />
The anatomic name of Cooper&#8217;s ligament is iliopectineal ligament. The Cooper&#8217;s ligament repair or McVay repair was popularized by Chester McVay (1911-1987). With Barry Aston, professor of anatomy at Northwestern University, McVay provided the modern description of the groin anatomy.</p>
<blockquote><p><strong>5. Antonio de Gimbernat, a Spanish surgeon and anatomist (1734-1816), had his interesting name attached to the lacunar ligament, which marks the medial margin of a groin area opening. What is the opening? What hernia protrudes into this opening?</strong> </p></blockquote>
<p>	Show answer<br />
The opening is the femoral canal, which is defined medially by the lacunar ligament, anteriorly by the inguinal ligament, posteriorly by the pectineal fascia, and laterally by the femoral vein. A femoral hernia protrudes into the femoral canal.</p>
<blockquote><p><strong>6. Indirect inguinal hernia (particularly in children) and hydrocele are associated with which congenital abnormality? </strong>	</p></blockquote>
<p>Show answer<br />
Persistence of an open processus vaginalis, in the case of a hernia, allows descent of bowel into the inguinal canal. With fluid accumulation, partial obstruction presents as a hydrocele of the spermatic cord.</p>
<blockquote><p><strong>7. What are the diagnostic criteria for hernia in an infant or child? </strong>	</p></blockquote>
<p>Show answer </p>
<p>    * Inguinal, scrotal, or labial lump that may or may not be reducible<br />
    * History of a lump seen by a health care provider<br />
    * History of a lump seen by the mother<br />
    * The &#8220;silk sign&#8221; (the feeling of rubbing together two surfaces of silk cloth when gently rubbing together the two surfaces of a hernia sac)<br />
    * An incarceration sometimes felt on rectal examination</p>
<blockquote><p><strong>8. What can be done to reduce an incarcerated hernia in an infant or child?</strong> </p></blockquote>
<p>	Show answer<br />
The four-point program is easier said than done, but it is worth the effort:</p>
<p>   1. Sedate the patient.<br />
   2. Place the patient in the Trendelenburg position.<br />
   3. Apply a cold pack (over petroleum gauze to avoid skin injury) in inguinal area.<br />
   4. In the absence of spontaneous reduction-and if the patient is quiet-use gentle manipulation.</p>
<blockquote><p><strong>9. How often can incarceration be successfully reduced? What should be done next? </strong></p></blockquote>
<p>	Show answer<br />
About 80% of incarcerated hernias can be reduced in children; in adults, the percentage is lower. Despite the fact that 80-90% of inguinal hernias occur in boys, most incarcerations occur in girls. The hernia should be repaired electively within a few days after incarceration. The 20% of hernias that are still incarcerated are operated immediately.</p>
<blockquote><p><strong>10. What is a Bassini repair? </strong></p></blockquote>
<p>	Show answer<br />
The Bassini repair sutures together the conjoined tendon and the shelving edge of the inguinal ligament up to the internal ring (Figure 56-1). This classic procedure, introduced in 1887 at the Italian Society of Surgery in Genoa, revolutionized hernia repair. Until recently, it has been the standard of repair. After graduation from medical school and while fighting for Italian independence, Eduardo Bassini (1844-1924) was bayoneted in the groin and, as a prisoner, was hospitalized for months with a fecal fistula.</p>
<p><img src="http://img3.raidpic.com/193.56.1.jpg" /></p>
<p><strong>Figure 56-1 The standard right inguinal hernia repair using the conjoined tendon and inguinal ligament.</strong></p>
<blockquote><p><strong>11. What is the recurrence rate with indirect and direct hernias that have been repaired with classic Bassini repair technique?</strong> </p></blockquote>
<p>	Show answer<br />
Over a follow-up period of 50 years, the recurrence rate of adult indirect hernias is 5-10%; of direct hernias, 15-30%.</p>
<blockquote><p><strong>12. Describe a McVay hernia repair. </strong></p></blockquote>
<p>	Show answer<br />
The line of interrupted sutures starts at a the pubic tubercle and joins the tendinous arch of the transversus abdominis muscle to Cooper&#8217;s ligament up to the femoral canal. At this point, two or three transitional sutures are placed from Cooper&#8217;s ligament to the anterior femoral fascia, effectively closing the medial extreme of the femoral canal. The final set of sutures joins the transversus abdominis arch and the anterior femoral fascia. The stitches usually incorporate the inguinal ligament at the upper limit of the repair, the site of the new internal inguinal ring and cord structures. About 15 years ago, McVay described laying in a mesh patch and stitching it, at its periphery, to the same anatomic structures. This application of mesh closely resembles the Lichtenstein repair (see question 17), except that it uses Cooper&#8217;s ligament.</p>
<blockquote><p><strong>13. For what type of hernias is the McVay Cooper&#8217;s ligament repair most useful? 	</strong></p></blockquote>
<p>Show answer<br />
Femoral and direct hernias.</p>
<blockquote><p><strong>14. What is the Shouldice repair? 	</strong></p></blockquote>
<p>Show answer<br />
The Shouldice repair, popularized at the Shouldice Clinic near Toronto, imbricates or overlays the transversalis fascia and conjoined tendon with four continuous lines, using two fine-wire sutures. The suture tract runs from the pubic tubercle to a new internal ring. Care is taken with the inferior epigastric vessels. The result is layered approximation of the conjoined tendon to the inguinal ligament tract.</p>
<blockquote><p><strong>15. What is the reported recurrence rate for the Shouldice repair? </strong></p></blockquote>
<p>	Show answer<br />
The recurrence rate is 1%, the lowest reported rate for nonmesh repairs of inguinal hernias in adults.</p>
<blockquote><p><strong>16. For what type of groin hernia is the Shouldice repair not appropriate?</strong></p></blockquote>
<p> 	Show answer<br />
Femoral hernia.</p>
<blockquote><p><strong>17. Describe the Lichtenstein repair. </strong></p></blockquote>
<p>	Show answer<br />
The Lichtenstein repair consists of a sutured patch of polypropylene mesh (Marlex, C.R. Bard, Inc., Covington, GA) that covers Hesselbach&#8217;s triangle and the indirect hernia area. It is considered a tension-free repair because the mesh is sutured in place without pulling ligaments or tissues together as in all other repairs. The mesh is divided at its upper end to wrap closely around the spermatic cord and its associated structures in the normal position of the internal inguinal canal. The Lichtenstein procedure is rapidly becoming the most widely used repair of adult inguinal hernia. The reported recurrence rate is < 1%.</p>
<blockquote><p><strong>18. What are the advantages of using the Marlex mesh?</strong></p></blockquote>
<p> 	Show answer<br />
Central to acceptance and success of the Lichtenstein hernia repair has been the development of and experience with the Marlex mesh. The monofilament mesh is strong, inert, and resistant to infection. The interstices are rapidly and completely infiltrated with fibroblasts, and the mesh is not subject to deterioration, rejection, or fragmentation. (See Figure 56-2.)</p>
<blockquote><p><strong>19. For what groin area is the Lichtenstein repair not appropriate?</strong></p></blockquote>
<p><img src="http://img7.raidpic.com/483.56.2.jpg" /></p>
<p><strong>Figure 56-2 The Marlex mesh repair of a right inguinal hernia. Note that the same structures are used but not brought together; thus, the name of the &#8220;tension-free&#8221; repair.</strong></p>
<blockquote><p><strong>20. Which type of repair is acceptable for the femoral hernia?</strong></p></blockquote>
<p> 	Show answer<br />
Several different repairs can be used. Mesh in the form of a plug can be inserted into the femoral canal and fixed in place. A McVay Cooper&#8217;s ligament repair can be done. A preperitoneal approach to the hernia can be used to suture or plug the defect. A suture repair or a sartorius facial flap applied from below the inguinal ligament in a femoral approach also may be used. The preperitoneal approach is increasingly used for complicated inguinal and femoral hernias.</p>
<blockquote><p><strong>21. What is the preperitoneal or Stoppa procedure?</strong></p></blockquote>
<p> 	Show answer<br />
The preperitoneal or Stoppa procedure is a groin hernia repair on the internal side of the abdominal wall between the peritoneum and fascial surfaces that do not open into the peritoneal cavity. The anatomic landmarks are very different and initially quite challenging to surgeons accustomed to the external abdominal wall approach. The technique is suited for recurrent hernias in which scarring and obliterated anatomy increase the risk of cord injury and recurrence. Other problems such as large hernias and femoral hernias are corrected with this approach. Conceptually, the laparoscopic hernia repair uses the same approach. (See Figure 56-3.)</p>
<blockquote><p><strong>22. Where are the spaces of Retzius and Bogros? Why are they increasingly important?</strong> 	</p></blockquote>
<p>Show answer<br />
Retzius&#8217; space is between the pubis and the urinary bladder. Bogros&#8217; space is between the peritoneum and the fascia and muscle planes on the posterior aspect of the abdominal wall below the umbilicus and down to Cooper&#8217;s ligament. Laterally, the space goes to the iliac spines. In either the open Stoppa procedure or the laparoscopic preperitoneal repair, the spaces of Retzius and Bogros are developed for mesh placement and surgical exposure.</p>
<blockquote><p><strong>23. How tight around the spermatic cord should a surgically fashioned, internal inguinal ring be? </strong></p></blockquote>
<p>	Show answer<br />
About 5 mm, which http://surgeryprocedure.info/wp-admin/media-upload.php?post_id=285&#038;type=image&#038;TB_iframe=true&#038;width=640&#038;height=525<br />
Add an Imageis less than a fingertip and more than a forceps tip.</p>
<p><img src="http://img7.raidpic.com/253.56.3.jpg" /><br />
<img src="http://img2.raidpic.com/253.56.3.jpg "></p>
<p><strong>Figure 56-3 The different appearance and landmarks are seen in the anterior view (above) and the posterior view (below) of the inguinal-femoral area. In the posterior view the importance of the inferior epigastric vessels, bladder, and Cooper&#8217;s ligament as anatomic landmarks is apparent</strong>.</p>
<blockquote><p><strong>24. What is the common fascial defect of larger indirect and all direct inguinal hernias</strong>? 	</p></blockquote>
<p>Show answer<br />
Weakness or attenuation of the transversalis fascia.</p>
<blockquote><p><strong>25. On examination, the femoral hernia may be confused with what other inguinal hernia? </strong>	</p></blockquote>
<p>Show answer<br />
The femoral hernia may be confused with a direct inguinal hernia because of the tendency of the femoral hernia to present at the lateral edge of the inguinal ligament.</p>
<p><em><strong>KEY POINTS: TYPES OF INGUINAL HERNIA REPAIR</strong></p>
<p>   1. The Bassini repair sutures together the conjoined tendon and the shelving edge of the inguinal ligament up to the internal ring.<br />
   2. The McVay repair is most useful for femoral and direct hernias.<br />
   3. The Shouldice repair imbricates the transversalis fascia and conjoined tendon with four continuous lines, using two fine-wire sutures (not appropriate for femoral hernias).<br />
   4. The Lichtenstein repair consists of a sutured patch of polyprolene mesh that covers Hesselbach&#8217;s triangle and the indirect hernia sac.</em></p>
<blockquote><p><strong><br />
26. What is the difference between an incarcerated and a strangulated hernia?</strong> </p></blockquote>
<p>	Show answer<br />
<strong>Incarcerated: </strong>structures in the hernia sac still have a good blood supply but are stuck in the sac because of adhesions or a narrow neck of the hernia sac.<br />
<strong>Strangulated:</strong> herniated structures, such as bowel or omentum, have lost their blood supply because of anatomic constriction at the neck of the hernia. The herniated, ischemic tissue is, therefore, in various stages of gangrenous changes. Strangulated hernias are surgical emergencies.</p>
<blockquote><p><strong>27. What operation is done for an uncomplicated indirect infant hernia? 	</strong></p></blockquote>
<p>Show answer<br />
High ligation of the hernia sac.</p>
<blockquote><p><strong>28. What operation is done for an uncomplicated indirect hernia in young adults?</strong> </p></blockquote>
<p>	Show answer<br />
The appropriate operation consists of high ligation and possibly one or two stitches in the transversalis fascia to tighten the internal ring. This is the basic Marcy technique, developed by Henry Orlando Marcy (1837-1924); it is smaller and more anatomically focused than the Bassini repair.</p>
<blockquote><p><strong>29. What operation is done for an uncomplicated but sizable direct hernia in elderly adults?</strong></p></blockquote>
<p> 	Show answer<br />
Traditionally, the Bassini or McVay repair was chosen. More recently, because of the low recurrence rate, the Shouldice or Lichtenstein repair is favored.</p>
<blockquote><p><strong>30. What organ systems should be reviewed with particular care in the work-up of patients with hernia (especially elderly patients with recent onset of hernia)?</strong> </p></blockquote>
<p>	Show answer<br />
The gastrointestinal, urinary, and pulmonary systems should be reviewed with particular care. One is looking for causes of chronic strain or sudden forces that may have induced the hernia. Straining during defecation or urination, unusual coughing, or difficulty with breathing, if corrected, may be of great value to the patient and reduce the chance of recurrent hernia.</p>
<blockquote><p><strong>31. What is a sliding hernia? </strong>	</p></blockquote>
<p>Show answer<br />
A sliding hernia is formed when a retroperitoneal organ protrudes (herniates) outside the abdominal cavity in such a manner that the organ itself and the overlying peritoneal surface constitute a side of the hernia sac.</p>
<blockquote><p><strong>32. What organs can be found in sliding hernias?</strong></p></blockquote>
<p> 	Show answer </p>
<p>    * Colon<br />
    * Cecum<br />
    * Appendix<br />
    * Ovary<br />
    * Bladder<br />
    * Fallopian tubes<br />
    * Uterus (rare)</p>
<blockquote><p><strong>33. What are common operative and postoperative complications of hernia repairs? </strong>	</p></blockquote>
<p>Show answer<br />
<strong>Intraoperative complications</strong></p>
<p>    * Injury to the spermatic cord, especially in children<br />
    * Injury to the spermatic vessels, resulting in atrophy or acute necrosis of testes<br />
    * Injury to the ilioinguinal nerve, genitofemoral nerve, and lateral femoral cutaneous nerve (the lateral femoral cutaneous nerve is uniquely vulnerable in laparoscopic and properitoneal procedures)<br />
    * Injury to the femoral vessels</p>
<p><strong>Postoperative complications</strong></p>
<p>    * Infection-high risk in children with diaper rash and patients with bowel injury or necrosis<br />
    * Hematoma-should resolve in time<br />
    * Nerve injury-the nerve is not always divided and, with time, may improve. If pain persists, try lidocaine block for both diagnosis and treatment. If a nerve block is not successful, one may consider reexploration to free the nerve from scar or to excise a postsurgical neuroma.</p>
<blockquote><p><strong>34. What are the common sites of hernia recurrence? 	</strong></p></blockquote>
<p>Show answer<br />
Direct hernias often recur at the pubic tubercle. Indirect hernias recur at the internal ring. The cause is usually related to poorly placed or insufficient stitches. Other possible causes include infection, poor tissue, poor collagen formation, or too much tension at the surgical suture line. A single line of repair under moderate tension fails in a significant number of patients, regardless of adequacy of repair or healing process. Tension is almost always bad in surgery.</p>
<blockquote><p><strong>35. How long should the patient avoid heavy lifting after a hernia repair? </strong>	</p></blockquote>
<p>Show answer<br />
The standard advice for decades has been 6 weeks. The current advice varies from no limitation with the Lichtenstein or preperitoneal repairs to 6 weeks for a Bassini repair. The self-limitation of pain is an excellent guide.</p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/abdominal-surgery/inguinal-hernia/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Heart Transplantation</title>
		<link>http://surgeryprocedure.info/transplantation/heart-transplantation</link>
		<comments>http://surgeryprocedure.info/transplantation/heart-transplantation#comments</comments>
		<pubDate>Tue, 14 Jul 2009 16:37:28 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRANSPLANTATION]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=456</guid>
		<description><![CDATA[91 HEART TRANSPLANTATION
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.
1. Who performed the first experimental heart-lung transplant?
 	Show answer
Alexis Carrel, a French-born American surgeon, developed the vascular techniques required for heart-lung transplantation and performed the first experimental heart-lung transplant in 1907. He transplanted the lungs, heart, aorta, and [...]]]></description>
			<content:encoded><![CDATA[<p><strong>91 HEART TRANSPLANTATION<br />
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.</strong></p>
<blockquote><p><strong>1. Who performed the first experimental heart-lung transplant?</strong></p></blockquote>
<p> 	Show answer<br />
Alexis Carrel, a French-born American surgeon, developed the vascular techniques required for heart-lung transplantation and performed the first experimental heart-lung transplant in 1907. He transplanted the lungs, heart, aorta, and vena cava of a 1-week-old cat into the neck of a large adult cat. For devising the technique of vascular anastomosis and other outstanding accomplishments, Carrel received the Nobel Prize in 1912 (the first Nobel Prize awarded to a scientist working in an American laboratory).<br />
<span id="more-456"></span></p>
<blockquote><p><strong>2. Who performed the first successful experimental heart-lung transplant?</strong></p></blockquote>
<p> 	Show answer<br />
V.P. Demikhov performed the first successful heart-lung transplant in a dog in 1962.</p>
<blockquote><p>3<strong>. Who developed the surgical strategy required for human heart transplantation?</strong> </p></blockquote>
<p>	Show answer<br />
Norman Shumway.</p>
<blockquote><p><strong>4. Who performed the first human heart transplant? When? </strong>	</p></blockquote>
<p>Show answer<br />
C.N. Bernard performed the first human heart transplant in December, 1967 (in Capetown, South Africa, after visiting Dr. Shumway), although Dr. Shumway set the stage by developing the technique in animals. Shumway and the Stanford group performed the first heart transplant in the United States and accomplished the first successful clinical series.</p>
<blockquote><p><strong>5. Who performed the first successful heart-lung transplant? When? </strong>	</p></blockquote>
<p>Show answer<br />
Dr. Bruce Reitz at Stanford in 1981 on a 21-year-old woman with pulmonary hypertension secondary to an atrial septal defect.</p>
<blockquote><p><strong>6. How many heart transplants are performed annually? Is the number increasing or decreasing?</strong></p></blockquote>
<p> 	Show answer<br />
In 1983 approximately 300 heart transplants were performed worldwide. By 1988, the number had rapidly increased to approximately 3000 and remains relatively stable between 3500 and 4000.</p>
<blockquote><p><strong>7. What anastomoses (surgical connections) must be performed for a combined heart and lungs transplant?</strong></p></blockquote>
<p> 	Show answer<br />
The operation requires only a right atrial-to-cava (inflow) anastomosis and an aortic (outflow) anastomosis with a connection at the trachea. Heart-lung transplant is less complicated (fewer anastomoses) than heart transplant alone, which may explain why heart-lung transplant was attempted first.<br />
8. What anastomoses must be performed for a heart transplant? 	Show answer<br />
Left atrial, right atrial, aortic, and pulmonary arterial.</p>
<blockquote><p><strong>9. Who is an acceptable cardiac donor?</strong> </p></blockquote>
<p>	Show answer </p>
<p>Acceptable cardiac donors meet the following criteria:</p>
<p>   1. Requirements for brain death<br />
   2. Consent from next of kin<br />
   3. ABO blood group compatibility with recipient<br />
   4. Within 20% of the same size as recipient<br />
   5. Absence of history of cardiac disease<br />
   6. Normal echocardiogram (ventricular wall motion)<br />
   7. Normal heart by inspection during organ recovery</p>
<blockquote><p><strong>10. Who is an acceptable cardiac recipient?</strong></p></blockquote>
<p> 	Show answer<br />
Although selection criteria are evolving as a result of improved techniques and outcomes, the following criteria are standard: age between newborn and 65 years; irremediable New York Heart Association Functional Class IV cardiac disease; normal renal, hepatic, pulmonary, and central nervous system function; pulmonary vascular resistance < 6-8 Wood units; and absence of malignancy, infection, recent pulmonary infarction, and severe peripheral vascular or cerebrovascular disease. Diabetes is a relative contraindication; the steroids used in posttransplant immunosuppression make diabetes difficult to manage. Also, normal psychological status has proven to be important.</p>
<blockquote><p><strong>11. What are the most common indications for heart transplant in adults and in children?</strong></p></blockquote>
<p> 	Show answer<br />
In adults, coronary artery disease (ischemic cardiomyopathy) and idiopathic cardiomyopathy each account for approximately 45% of transplants.<br />
In children, congenital heart disease and cardiomyopathy are most common, with hypoplastic left heart being the most common congenital malformation requiring heart transplantation.</p>
<blockquote><p><strong>12. What percentage of potential recipients (on the transplant list) die while waiting for a heart transplant?</strong> </p></blockquote>
<p>	Show answer<br />
20%.</p>
<blockquote><p><strong>13. At what point does donor heart ischemic time influence mortality?</strong> </p></blockquote>
<p>	Show answer<br />
Donor heart ischemic time > 6 hours definitely increases mortality. Ischemic times between 4 and 6 hours stun the donor heart. Most transplant teams try to keep ischemic times (from donor harvest to perfusion in the recipient) to < 4 hours.</p>
<blockquote><p><strong>14. Who pioneered hypothermic myocardial preservation? </strong>	</p></blockquote>
<p>Show answer<br />
Henry Swan at the University of Colorado. He submerged anesthetized children in a bathtub of ice water before cardiac procedures.</p>
<blockquote><p><strong>15. How is cardiac allograft rejection prevented?</strong> 	</p></blockquote>
<p>Show answer<br />
Pharmacologically induced immunosuppression is performed by using one of two protocols. The first is triple therapy, which combines cyclosporine, azathioprine, and prednisone. The second major protocol incorporates the monoclonal antibody OKT3 into the triple therapy protocol. OKT3 is substituted for cyclosporine for the first 2 weeks after transplant.</p>
<blockquote><p><strong>16. What is OKT3? 	</strong></p></blockquote>
<p>Show answer<br />
OKT3 is a mouse monoclonal antibody that binds to and blocks the T-cell CD3 receptor. A monoclonal antibody is an antibody generated from the clones of a single cell. For instance, a single B cell, which recognizes the CD3 receptor as an antigen (foreign), is immortalized in cell culture and produces the monoclonal antibody in limitless supply. The CD3 receptor, which is common to all T cells, is important for antigen recognition and T-cell activation; therefore, OKT3 is highly immunosuppressive.<br />
<em><strong>KEY POINTS: CRITERIA FOR ACCEPTABLE HEART DONORS</strong></p>
<p>   1. Donors must meet the criteria for brain death.<br />
   2. Consent from donor&#8217;s next of kin.<br />
   3. ABO blood group compatibility with recipient.<br />
   4. Donor must be within 20% of same size as recipient.<br />
   5. Donor must have no history of cardiac disease and a normal echocardiogram.<br />
   6. Donor heart must appear normal by inspection during organ recovery.</em></p>
<blockquote><p><strong><br />
17. What complications are associated with the use of OKT3? </strong></p></blockquote>
<p>	Show answer<br />
OKT3 may have severe side effects, including pulmonary edema and high fevers, that result from transient cytokine release, which may occur when OKT3 binds to the T-cell activation site. Because OKT3 is an antigen (an antibody from a different species [i.e., a mouse]), patients develop anti-OKT3 antibodies fairly quickly; the result is that OKT3 can only be used to treat one rejection episode. Severe side effects occur in < 5% of patients.</p>
<blockquote><p><strong>18. Does HLA mismatch influence the incidence of rejection after heart transplantation? Is HLA typing routinely performed before heart transplantation? </strong>	</p></blockquote>
<p>Show answer<br />
Yes and no. In a multi-institutional, multivariate analysis of 1719 cardiac transplant recipients by Jarcho et al., HLA mismatch increased the incidence of rejection. However, HLA typing is not routinely done before heart transplantation because it takes too long. In addition, with three of six mismatches, there was still only a trend toward increased rejection-related deaths (P = 0.14). If longer organ preservation times can be achieved, donor/recipient HLA matching will become feasible and should improve survival rates. Again, ABO blood group compatibility does influence graft survival.</p>
<blockquote><p><strong>19. What are the major complications of heart transplantation? </strong></p></blockquote>
<p>	Show answer </p>
<p>    * Allograft rejection (days to weeks)<br />
    * Infection (months)<br />
    * Transplant coronary artery disease (years)</p>
<blockquote><p><strong>20. What is the incidence of transplant coronary artery disease? What are the risk factors? </strong>	</p></blockquote>
<p>Show answer<br />
Nearly 50% of patients have angiographic evidence of coronary artery disease by 5 years after transplant. However, only approximately 10% develop at least 70% stenosis (hemodynamically significant stenosis). Severe stenosis is highly predictive of the need for retransplantation. Risk factors for transplant coronary artery disease include male gender of the donor or recipient, older donor age, and donor hypertension.</p>
<blockquote><p><strong>21. How is cardiac allograft rejection diagnosed? </strong>	</p></blockquote>
<p>Show answer<br />
Clinical suspicion is raised by new-onset cardiac arrhythmia, fever, or hypotension. Diagnosis depends on endomyocardial biopsy, which is performed at regular intervals to detect histologic evidence of rejection before signs or symptoms occur. Radionuclide ventriculography and echocardiography are useful adjuncts in following the hemodynamic manifestations of rejection. Electrocardiography itself is not very sensitive in the diagnosis of rejection.</p>
<blockquote><p>
<strong>22. Are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (&#8221;statin&#8221; drugs) generally recommended for post-cardiac transplant patients? </strong></p></blockquote>
<p>	Show answer<br />
Yes. Hypercholesterolemia is common after transplantation, and HMG-CoA reductase inhibitors reduce the development of the diffuse atherosclerosis that tends to occur in transplanted hearts. In addition, statins have an early effect on mortality, which suggests that these drugs may also have immunosuppressive effects.</p>
<blockquote><p><strong>23. What are ventricular assist devices (VADs)? </strong></p></blockquote>
<p>	Show answer<br />
These devices are designed to unload either the right (RVAD) or left (LVAD) ventricle while supporting the pulmonary or systemic circulation. Patients with these VADs may be ambulatory, and the devices may be worn for weeks to months. VADs may be used as a bridge to transplant (when the patient is listed for transplantation) or as destination therapy (when no transplant is planned).</p>
<blockquote><p><strong>24. What is the most serious complication of transvenous endomyocardial biopsy?</strong> </p></blockquote>
<p>	Show answer<br />
Cardiac perforation occurs in 0.5% of cases. This can rapidly lead to tamponade and circulatory collapse.</p>
<blockquote><p><strong>25. What is the typical infection pattern for a posttransplant patient? 	</strong></p></blockquote>
<p>Show answer </p>
<p>    * First postoperative month: conventional bacterial pathogens encountered in surgical patients<br />
    * 1-4 months: opportunistic pathogens, especially cytomegalovirus<br />
    * >4 months: both conventional and opportunistic infections</p>
<blockquote><p><strong>26. Is the transplanted heart denervated?</strong> </p></blockquote>
<p>	Show answer<br />
Initially, yes, but it is believed that partial reinnervation begins within 1 year. Because of this, the heart&#8217;s anatomically mediated reflexes are blunted (e.g., higher resting heart rate because of decreased or absent vagal tone).</p>
<blockquote><p><strong>27. Can one heart be successfully transplanted twice? </strong>	</p></blockquote>
<p>Show answer<br />
Yes. Meiser et al. transplanted the same heart a second time on March 19, 1991, 42 hours after the initial transplantation. Second transplant of the same heart has since been reported by others.</p>
<blockquote><p><strong>28. What is &#8220;domino heart transplant&#8221;? </strong>	</p></blockquote>
<p>Show answer<br />
The good heart from a heart-lung recipient is transplanted into a patient requiring a heart transplant. Some patients with primary lung dysfunction have secondary irreversible cardiac dysfunction (i.e., Eisenmenger&#8217;s syndrome); others, however, such as patients with cystic fibrosis, have good cardiac function. Patients with good cardiac function may serve as donors and increase the donor pool.</p>
<blockquote><p><strong>29. Is the heart capable of making tumor necrosis factor (TNF)? What does TNF have to do with heart transplantation? </strong></p></blockquote>
<p>	Show answer<br />
TNF, typically described as a macrophage- or monocyte-derived inflammatory cytokine, is also produced in large quantities by the heart. TNF released by the heart after ischemia-reperfusion probably contributes to immediate injury (dysfunction) and possibly to later rejection. Anti-TNF strategies are intuitively promising (but undocumented) therapeutic strategies.</p>
<blockquote><p><strong>30. What is the overall 30-day mortality rate after heart transplant? What is the breakdown in mortality between adult and pediatric patients?</strong></p></blockquote>
<p> 	Show answer<br />
The registry of the International Society for Heart and Lung Transplantation, which has data for approximately 45,000 heart transplants, has recorded a 30-day mortality rate of 10%. The 30-day mortality rate for adult recipients is about 8%; for pediatric recipients, it is slightly higher.</p>
<blockquote><p><strong>31. What are the 5- and 10-year actuarial survival rates for heart transplant recipients? 	</strong></p></blockquote>
<p>Show answer </p>
<blockquote><p><strong>75% and 50%, respectively (and the quality of life is dramatically improved).<br />
32. What work remains to be done in heart transplantation? 	</strong></p></blockquote>
<p>Show answer<br />
The future of heart transplantation is bright. Knowledge gained in experimental myocardial ischemia-reperfusion injury and protection is accelerating. New, exciting ways to manipulate myocardial immunology (e.g., signal transduction, gene therapy, chimerism) will further extend donor ischemic times and improve postoperative myocardial function and graft tolerance. Ultimately, genetic alteration of donor hearts will increase the donor pool.</p>
<p><strong><br />
References</strong><br />
WEB SITE<br />
<a href="http://www.transplantation-soc.org/">http://www.transplantation-soc.org</a><br />
BIBLIOGRAPHY<br />
1. Hosenpud JD, Bennett LE, Keck BM, et al: The Registry of the International Society for Heart and Lung Transplantation: Eighteenth official report-2001. J Heart Lung Transplant 20:805-815, 2001.<br />
2. Kobashigawa JA: Advances in immunosuppression for heart transplantation. Adv Card Surg 10:155-174, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9917904&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9917904">Similar articles</a><br />
3. Kupiec-Weglinski JW: Graft rejection in sensitized recipients. Ann Transplant 1:34-40, 1996. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9869935&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9869935">Similar articles</a><br />
4. Kuvin JT, Kimmelstiel CD: Infectious causes of atherosclerosis. Am Heart J 137:216-226, 1999. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9924154&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9924154">Similar articles</a><br />
5. Leier CV, Binkley PF: Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 41:207-224, 1998.<br />
6. Meldrum DR: Tumor necrosis factor in the heart [review]. Am J Physiol 274:R577, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9530222">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9530222&#038;dopt=Abstract">Similar articles</a><br />
7. Meldrum DR, Dinarello CA, Meng X, et al: Ischemic preconditioning decreases post-ischemic myocardial TNF: Potential ultimate effector mechanism of preconditioning. Circulation 98:II214-II218, 1998.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9852905&#038;dopt=Abstract"> Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9852905">Similar articles</a><br />
8. Mindan JP, Panizo A: Pathology of heart transplant. Curr Top Pathol 92:137-165, 1999.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9919809"> Similar articles</a><br />
9. Orbaek Andersen H: Heart allograft vascular disease: An obliterative vascular disease in transplanted hearts. Atherosclerosis 142:243-263, 1999. Medline Similar articles<br />
10. Pillai R, Bando K, Schueler S, et al: Leukocyte depletion results in excellent heart-lung function after 12 hours of storage. Ann Thorac Surg 50:211-214, 1990. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10030375&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10030375">Similar articles</a><br />
11. Reardon MJ, Letsou GV, Anderson JE, et al: Orthotopic cardiac transplantation after minimally invasive direct coronary artery bypass. J Thorac Cardiovasc Surg 117:390-391, 1999.<br />
12. Spann JC, Van Meter C: Cardiac transplantation. Surg Clin North Am 78:679-690, 1998. Medline Similar articles</p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/transplantation/heart-transplantation/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title></title>
		<link>http://surgeryprocedure.info/transplantation/457</link>
		<comments>http://surgeryprocedure.info/transplantation/457#comments</comments>
		<pubDate>Mon, 13 Jul 2009 19:31:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRANSPLANTATION]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=457</guid>
		<description><![CDATA[91 HEART TRANSPLANTATION
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.
1. Who performed the first experimental heart-lung transplant? 	
Show answer
Alexis Carrel, a French-born American surgeon, developed the vascular techniques required for heart-lung transplantation and performed the first experimental heart-lung transplant in 1907. He transplanted the lungs, heart, aorta, and [...]]]></description>
			<content:encoded><![CDATA[<p><strong>91 HEART TRANSPLANTATION<br />
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.</strong></p>
<blockquote><p><strong>1. Who performed the first experimental heart-lung transplant? </strong>	</p></blockquote>
<p>Show answer<br />
Alexis Carrel, a French-born American surgeon, developed the vascular techniques required for heart-lung transplantation and performed the first experimental heart-lung transplant in 1907. He transplanted the lungs, heart, aorta, and vena cava of a 1-week-old cat into the neck of a large adult cat. For devising the technique of vascular anastomosis and other outstanding accomplishments, Carrel received the Nobel Prize in 1912 (the first Nobel Prize awarded to a scientist working in an American laboratory).<br />
<span id="more-457"></span><br />
<!--more--></p>
<blockquote><p><strong>2. Who performed the first successful experimental heart-lung transplant? 	</strong></p></blockquote>
<p>Show answer<br />
V.P. Demikhov performed the first successful heart-lung transplant in a dog in 1962.</p>
<blockquote><p><strong>3. Who developed the surgical strategy required for human heart transplantation? 	</strong></p></blockquote>
<p>Show answer<br />
Norman Shumway.</p>
<blockquote><p><strong>4. Who performed the first human heart transplant? When? </strong></p></blockquote>
<p>	Show answer<br />
C.N. Bernard performed the first human heart transplant in December, 1967 (in Capetown, South Africa, after visiting Dr. Shumway), although Dr. Shumway set the stage by developing the technique in animals. Shumway and the Stanford group performed the first heart transplant in the United States and accomplished the first successful clinical series.</p>
<blockquote><p><strong>5. Who performed the first successful heart-lung transplant? When? </strong></p></blockquote>
<p>	Show answer<br />
Dr. Bruce Reitz at Stanford in 1981 on a 21-year-old woman with pulmonary hypertension secondary to an atrial septal defect.</p>
<blockquote><p><strong>6. How many heart transplants are performed annually? Is the number increasing or decreasing?</strong></p></blockquote>
<p> 	Show answer<br />
In 1983 approximately 300 heart transplants were performed worldwide. By 1988, the number had rapidly increased to approximately 3000 and remains relatively stable between 3500 and 4000.</p>
<blockquote><p><strong>7. What anastomoses (surgical connections) must be performed for a combined heart and lungs transplant? </strong>	</p></blockquote>
<p>Show answer<br />
The operation requires only a right atrial-to-cava (inflow) anastomosis and an aortic (outflow) anastomosis with a connection at the trachea. Heart-lung transplant is less complicated (fewer anastomoses) than heart transplant alone, which may explain why heart-lung transplant was attempted first.</p>
<blockquote><p><strong>8. What anastomoses must be performed for a heart transplant?</strong> 	</p></blockquote>
<p>Show answer<br />
Left atrial, right atrial, aortic, and pulmonary arterial.</p>
<blockquote><p><strong>9. Who is an acceptable cardiac donor? </strong>	</p></blockquote>
<p>Show answer </p>
<p>Acceptable cardiac donors meet the following criteria:</p>
<p>   1. Requirements for brain death<br />
   2. Consent from next of kin<br />
   3. ABO blood group compatibility with recipient<br />
   4. Within 20% of the same size as recipient<br />
   5. Absence of history of cardiac disease<br />
   6. Normal echocardiogram (ventricular wall motion)<br />
   7. Normal heart by inspection during organ recovery</p>
<blockquote><p><strong>10. Who is an acceptable cardiac recipient? </strong></p></blockquote>
<p>	Show answer<br />
Although selection criteria are evolving as a result of improved techniques and outcomes, the following criteria are standard: age between newborn and 65 years; irremediable New York Heart Association Functional Class IV cardiac disease; normal renal, hepatic, pulmonary, and central nervous system function; pulmonary vascular resistance < 6-8 Wood units; and absence of malignancy, infection, recent pulmonary infarction, and severe peripheral vascular or cerebrovascular disease. Diabetes is a relative contraindication; the steroids used in posttransplant immunosuppression make diabetes difficult to manage. Also, normal psychological status has proven to be important.</p>
<blockquote><p><strong>11. What are the most common indications for heart transplant in adults and in children? </strong>	</p></blockquote>
<p>Show answer<br />
In adults, coronary artery disease (ischemic cardiomyopathy) and idiopathic cardiomyopathy each account for approximately 45% of transplants.<br />
In children, congenital heart disease and cardiomyopathy are most common, with hypoplastic left heart being the most common congenital malformation requiring heart transplantation.</p>
<blockquote><p><strong>12. What percentage of potential recipients (on the transplant list) die while waiting for a heart transplant?</strong></p></blockquote>
<p> 	Show answer<br />
20%.</p>
<blockquote><p><strong>13. At what point does donor heart ischemic time influence mortality?</strong> </p></blockquote>
<p>	Show answer<br />
Donor heart ischemic time > 6 hours definitely increases mortality. Ischemic times between 4 and 6 hours stun the donor heart. Most transplant teams try to keep ischemic times (from donor harvest to perfusion in the recipient) to < 4 hours.</p>
<blockquote><p><strong>14. Who pioneered hypothermic myocardial preservation?</strong></p></blockquote>
<p> 	Show answer<br />
Henry Swan at the University of Colorado. He submerged anesthetized children in a bathtub of ice water before cardiac procedures.</p>
<blockquote><p><strong>15. How is cardiac allograft rejection prevented? </strong>	</p></blockquote>
<p>Show answer<br />
Pharmacologically induced immunosuppression is performed by using one of two protocols. The first is triple therapy, which combines cyclosporine, azathioprine, and prednisone. The second major protocol incorporates the monoclonal antibody OKT3 into the triple therapy protocol. OKT3 is substituted for cyclosporine for the first 2 weeks after transplant.</p>
<blockquote><p><strong>16. What is OKT3? 	</strong></p></blockquote>
<p>Show answer<br />
OKT3 is a mouse monoclonal antibody that binds to and blocks the T-cell CD3 receptor. A monoclonal antibody is an antibody generated from the clones of a single cell. For instance, a single B cell, which recognizes the CD3 receptor as an antigen (foreign), is immortalized in cell culture and produces the monoclonal antibody in limitless supply. The CD3 receptor, which is common to all T cells, is important for antigen recognition and T-cell activation; therefore, OKT3 is highly immunosuppressive.<br />
<em><br />
<strong>KEY POINTS: CRITERIA FOR ACCEPTABLE HEART DONORS</strong></p>
<p>   1. Donors must meet the criteria for brain death.<br />
   2. Consent from donor&#8217;s next of kin.<br />
   3. ABO blood group compatibility with recipient.<br />
   4. Donor must be within 20% of same size as recipient.<br />
   5. Donor must have no history of cardiac disease and a normal echocardiogram.<br />
   6. Donor heart must appear normal by inspection during organ recovery.</em></p>
<blockquote><p>
<strong>17. What complications are associated with the use of OKT3? 	</strong></p></blockquote>
<p>Show answer<br />
OKT3 may have severe side effects, including pulmonary edema and high fevers, that result from transient cytokine release, which may occur when OKT3 binds to the T-cell activation site. Because OKT3 is an antigen (an antibody from a different species [i.e., a mouse]), patients develop anti-OKT3 antibodies fairly quickly; the result is that OKT3 can only be used to treat one rejection episode. Severe side effects occur in < 5% of patients.</p>
<blockquote><p><strong>18. Does HLA mismatch influence the incidence of rejection after heart transplantation? Is HLA typing routinely performed before heart transplantation? 	</strong></p></blockquote>
<p>Show answer<br />
Yes and no. In a multi-institutional, multivariate analysis of 1719 cardiac transplant recipients by Jarcho et al., HLA mismatch increased the incidence of rejection. However, HLA typing is not routinely done before heart transplantation because it takes too long. In addition, with three of six mismatches, there was still only a trend toward increased rejection-related deaths (P = 0.14). If longer organ preservation times can be achieved, donor/recipient HLA matching will become feasible and should improve survival rates. Again, ABO blood group compatibility does influence graft survival.</p>
<blockquote><p><strong>19. What are the major complications of heart transplantation?</strong> </p></blockquote>
<p>	Show answer </p>
<p>    * Allograft rejection (days to weeks)<br />
    * Infection (months)<br />
    * Transplant coronary artery disease (years)</p>
<blockquote><p><strong>20. What is the incidence of transplant coronary artery disease? What are the risk factors? </strong></p></blockquote>
<p>	Show answer<br />
Nearly 50% of patients have angiographic evidence of coronary artery disease by 5 years after transplant. However, only approximately 10% develop at least 70% stenosis (hemodynamically significant stenosis). Severe stenosis is highly predictive of the need for retransplantation. Risk factors for transplant coronary artery disease include male gender of the donor or recipient, older donor age, and donor hypertension.</p>
<blockquote><p><strong>21. How is cardiac allograft rejection diagnosed? 	</strong></p></blockquote>
<p>Show answer<br />
Clinical suspicion is raised by new-onset cardiac arrhythmia, fever, or hypotension. Diagnosis depends on endomyocardial biopsy, which is performed at regular intervals to detect histologic evidence of rejection before signs or symptoms occur. Radionuclide ventriculography and echocardiography are useful adjuncts in following the hemodynamic manifestations of rejection. Electrocardiography itself is not very sensitive in the diagnosis of rejection.</p>
<blockquote><p><strong>22. Are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (&#8221;statin&#8221; drugs) generally recommended for post-cardiac transplant patients? 	</strong</p></blockquote>
<p>>Show answer<br />
Yes. Hypercholesterolemia is common after transplantation, and HMG-CoA reductase inhibitors reduce the development of the diffuse atherosclerosis that tends to occur in transplanted hearts. In addition, statins have an early effect on mortality, which suggests that these drugs may also have immunosuppressive effects.</p>
<blockquote><p><strong>23. What are ventricular assist devices (VADs)?</strong> 	</p></blockquote>
<p>Show answer<br />
These devices are designed to unload either the right (RVAD) or left (LVAD) ventricle while supporting the pulmonary or systemic circulation. Patients with these VADs may be ambulatory, and the devices may be worn for weeks to months. VADs may be used as a bridge to transplant (when the patient is listed for transplantation) or as destination therapy (when no transplant is planned).</p>
<blockquote><p><strong>24. What is the most serious complication of transvenous endomyocardial biopsy? </strong>	</p></blockquote>
<p>Show answer<br />
Cardiac perforation occurs in 0.5% of cases. This can rapidly lead to tamponade and circulatory collapse.</p>
<blockquote><p><strong>25. What is the typical infection pattern for a posttransplant patient?</strong> 	</p></blockquote>
<p>Show answer </p>
<p>    * First postoperative month: conventional bacterial pathogens encountered in surgical patients<br />
    * 1-4 months: opportunistic pathogens, especially cytomegalovirus<br />
    * >4 months: both conventional and opportunistic infections</p>
<blockquote><p><strong>26. Is the transplanted heart denervated? 	</strong></p></blockquote>
<p>Show answer<br />
Initially, yes, but it is believed that partial reinnervation begins within 1 year. Because of this, the heart&#8217;s anatomically mediated reflexes are blunted (e.g., higher resting heart rate because of decreased or absent vagal tone).</p>
<blockquote><p><strong>27. Can one heart be successfully transplanted twice?</strong></p></blockquote>
<p> 	Show answer<br />
Yes. Meiser et al. transplanted the same heart a second time on March 19, 1991, 42 hours after the initial transplantation. Second transplant of the same heart has since been reported by others.</p>
<blockquote><p><strong>28. What is &#8220;domino heart transplant&#8221;? </strong>	</p></blockquote>
<p>Show answer<br />
The good heart from a heart-lung recipient is transplanted into a patient requiring a heart transplant. Some patients with primary lung dysfunction have secondary irreversible cardiac dysfunction (i.e., Eisenmenger&#8217;s syndrome); others, however, such as patients with cystic fibrosis, have good cardiac function. Patients with good cardiac function may serve as donors and increase the donor pool.</p>
<p><strong><br />
<blockquote>29. Is the heart capable of making tumor necrosis factor (TNF)? What does TNF have to do with heart transplantation? 	</p></blockquote>
<p></strong></p>
<p>Show answer<br />
TNF, typically described as a macrophage- or monocyte-derived inflammatory cytokine, is also produced in large quantities by the heart. TNF released by the heart after ischemia-reperfusion probably contributes to immediate injury (dysfunction) and possibly to later rejection. Anti-TNF strategies are intuitively promising (but undocumented) therapeutic strategies.</p>
<blockquote><p><strong>30. What is the overall 30-day mortality rate after heart transplant? What is the breakdown in mortality between adult and pediatric patients? </strong>	</p></blockquote>
<p>Show answer<br />
The registry of the International Society for Heart and Lung Transplantation, which has data for approximately 45,000 heart transplants, has recorded a 30-day mortality rate of 10%. The 30-day mortality rate for adult recipients is about 8%; for pediatric recipients, it is slightly higher.</p>
<blockquote><p><strong>31. What are the 5- and 10-year actuarial survival rates for heart transplant recipients? 	</strong></p></blockquote>
<p>Show answer<br />
75% and 50%, respectively (and the quality of life is dramatically improved).</p>
<blockquote><p><strong>32. What work remains to be done in heart transplantation?</strong> </p></blockquote>
<p>	Show answer<br />
The future of heart transplantation is bright. Knowledge gained in experimental myocardial ischemia-reperfusion injury and protection is accelerating. New, exciting ways to manipulate myocardial immunology (e.g., signal transduction, gene therapy, chimerism) will further extend donor ischemic times and improve postoperative myocardial function and graft tolerance. Ultimately, genetic alteration of donor hearts will increase the donor pool.</p>
<p><strong>References</strong><br />
WEB SITE<br />
<a href="http://www.transplantation-soc.org/">http://www.transplantation-soc.org</a><br />
BIBLIOGRAPHY<br />
1. Hosenpud JD, Bennett LE, Keck BM, et al: The Registry of the International Society for Heart and Lung Transplantation: Eighteenth official report-2001. J Heart Lung Transplant 20:805-815, 2001.<br />
2. Kobashigawa JA: Advances in immunosuppression for heart transplantation. Adv Card Surg 10:155-174, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9917904&#038;dopt=Abstract">Medline</a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9917904"> Similar articles</a><br />
3. Kupiec-Weglinski JW: Graft rejection in sensitized recipients. Ann Transplant 1:34-40, 1996.<br />
4. Kuvin JT, Kimmelstiel CD: Infectious causes of atherosclerosis. Am Heart J 137:216-226, 1999. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9924154&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9924154">Similar articles</a><br />
5. Leier CV, Binkley PF: Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis 41:207-224, 1998.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9872607&#038;dopt=Abstract"> Medline</a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9872607"> Similar articles</a><br />
6. Meldrum DR: Tumor necrosis factor in the heart [review]. Am J Physiol 274:R577, 1998.<br />
7. Meldrum DR, Dinarello CA, Meng X, et al: Ischemic preconditioning decreases post-ischemic myocardial TNF: Potential ultimate effector mechanism of preconditioning. Circulation 98:II214-II218, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9852905&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9852905">Similar articles</a><br />
8. Mindan JP, Panizo A: Pathology of heart transplant. Curr Top Pathol 92:137-165, 1999.<br />
9. Orbaek Andersen H: Heart allograft vascular disease: An obliterative vascular disease in transplanted hearts. Atherosclerosis 142:243-263, 1999. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10030375&#038;dopt=Abstract">Medline</a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10030375"> Similar articles</a><br />
10. Pillai R, Bando K, Schueler S, et al: Leukocyte depletion results in excellent heart-lung function after 12 hours of storage. Ann Thorac Surg 50:211-214, 1990.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=2383105&#038;dopt=Abstract"> Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=2383105">Similar articles</a><br />
11. Reardon MJ, Letsou GV, Anderson JE, et al: Orthotopic cardiac transplantation after minimally invasive direct coronary artery bypass. J Thorac Cardiovasc Surg 117:390-391, 1999.<br />
12. Spann JC, Van Meter C: Cardiac transplantation. Surg Clin North Am 78:679-690, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9891570&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9891570">Similar articles</a></p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/transplantation/457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lung Transplantation</title>
		<link>http://surgeryprocedure.info/transplantation/lung-transplantation</link>
		<comments>http://surgeryprocedure.info/transplantation/lung-transplantation#comments</comments>
		<pubDate>Mon, 13 Jul 2009 19:38:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRANSPLANTATION]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=459</guid>
		<description><![CDATA[92 LUNG TRANSPLANTATION
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.
1. What are the general types of lung transplants? 	
Show answer
Single, double (bilateral), and heart-lung.

2. Which human organ transplant was performed first, the heart or the lung? 	
Show answer
Although heart transplantation has progressed more rapidly, the first lung transplant [...]]]></description>
			<content:encoded><![CDATA[<p><strong>92 LUNG TRANSPLANTATION<br />
Daniel R. Meldrum M.D., Azad Raiesdana M.D., Jeffrey A. Breall M.D., John W. Brown M.D.</strong></p>
<blockquote><p><strong>1. What are the general types of lung transplants? </strong>	</p></blockquote>
<p>Show answer<br />
Single, double (bilateral), and heart-lung.<br />
<span id="more-459"></span></p>
<blockquote><p><strong>2. Which human organ transplant was performed first, the heart or the lung? 	</strong></p></blockquote>
<p>Show answer<br />
Although heart transplantation has progressed more rapidly, the first lung transplant preceded the first heart transplant.</p>
<blockquote><p><strong>3. Who performed the first human lung transplant? When? </strong>	</p></blockquote>
<p>Show answer<br />
James Hardy performed the first human lung transplant in 1963; however, more than 20 years passed before lung transplantation was performed routinely in clinical practice (during that 20 year period, only 1 patient did well enough to leave the hospital). This delay was caused by initial graft failure secondary to inadequate organ preservation, long ischemic times, lack of good immunosuppressive agents, and technical difficulties (primarily with the bronchial-not the vascular-anastomoses).</p>
<blockquote><p><strong>4. Who is a candidate for a lung transplant?</strong> </p></blockquote>
<p>	Show answer<br />
Candidates include patients with no other medical or surgical alternative who are likely to die of pulmonary disease within 18 months, are younger than 65 years, are not ventilator dependent, and do not have a history of malignancy. Psychological stability in the recipient is also important.</p>
<blockquote><p><strong>5. What are the most common indications for single lung transplant? </strong>	</p></blockquote>
<p>Show answer </p>
<p>    * Emphysema (40%)<br />
    * Idiopathic pulmonary fibrosis (20%)<br />
    * Alpha-1 antitrypsin deficiency (11%)<br />
    * Primary pulmonary hypertension and pulmonary hypertension secondary to correctable congenital heart disease (10%)</p>
<blockquote><p>
<strong>6. What are the most common indications for a double-lung transplant?</strong> </p></blockquote>
<p>	Show answer </p>
<p>    * Cystic fibrosis (35%)<br />
    * Emphysema (20%)<br />
    * Alpha-1 antitrypsin deficiency (11%)<br />
    * Primary pulmonary hypertension and pulmonary hypertension secondary to correctable congenital heart disease (20%)<br />
    * Idiopathic pulmonary fibrosis (8%)</p>
<blockquote><p><strong>7. What are the most common indications for heart-lung transplant? 	</strong></p></blockquote>
<p>Show answer<br />
Primary pulmonary hypertension (30%) and cystic fibrosis (16%) are instances in which bad lungs have ruined a good heart. Conversely, with congenital heart disease (27%), a bad heart has destroyed good lungs.</p>
<blockquote><p><strong>8. What is sewn to what during a single-lung transplant? A double-lung transplant? </strong>	</p></blockquote>
<p>Show answer<br />
During a single-lung transplant, recipient-to-graft bronchial, pulmonary artery, and pulmonary vein (atrial cuff) anastomoses are required. Anastomoses for double transplant are the same; however, cardiopulmonary bypass is required more often during double-lung transplant. During implantation of the second lung, diversion of the entire cardiac output to the freshly ischemic lung often results in reperfusion lung edema and hypoxemia.</p>
<blockquote><p><strong>9. Which diagnoses carry the best results for single-lung transplants?</strong> 	</p></blockquote>
<p>Show answer<br />
Patients with emphysema and alpha-1 antitrypsin deficiency do significantly better, with 1-year survival rates of 80%.</p>
<blockquote><p><strong>10. Why is the number of combined heart-lung transplants performed annually decreasing? 	</strong></p></blockquote>
<p>Show answer<br />
Approximately 250 heart-lung transplants were performed in 1990; the number has decreased to approximately 150 in 1999. As the results of single- and double-lung transplants have improved, the need to perform heart-lung transplants in patients with isolated pulmonary disease has been obviated.</p>
<blockquote><p><strong>11. What are the most common complications after lung transplant?</strong> </p></blockquote>
<p>	Show answer </p>
<p>    * Airway surgical healing defects (early)<br />
    * Rejection (early)<br />
    * Bacterial and cytomegalovirus infections (weeks to months)<br />
    * Bronchiolitis obliterans (months to years)</p>
<blockquote><p><strong><strong><br />
12. What is bronchiolitis obliterans?</strong></strong> </p></blockquote>
<p>	Show answer<br />
Bronchiolitis obliterans, a major cause of long-term morbidity after lung transplantation, is a process in which membranous and respiratory bronchioles demonstrate histologic evidence of subepithelial scarring that eventually progresses to occlusion of the bronchiolar lumen. Clinically, it is characterized by dyspnea and airflow obstruction.</p>
<blockquote><p><strong>13. What are the risk factors for the development of bronchiolitis obliterans after lung transplant?</strong> 	</p></blockquote>
<p>Show answer<br />
Donor age > 40 years and donor ischemic times > 6 hours.</p>
<blockquote><p><strong>14. How is lung transplant rejection diagnosed? </strong>	</p></blockquote>
<p>Show answer<br />
Unlike heart transplants, the diagnosis of rejection in transplanted lungs is imprecise and based on a collection of symptoms and signs. Decreased oxygen saturation, fever, decreased exercise tolerance, and radiologic infiltrate suggest rejection. Sequential quantitative lung perfusion scans that demonstrate a decrease in perfusion are helpful in the diagnosis of rejection after single-lung transplants. Transbronchial biopsy is useful after single- and double-lung transplants.</p>
<blockquote><p><strong>15. Describe the phenomenon of chimerism in transplantation.</strong> </p></blockquote>
<p>	Show answer<br />
Chimerism is leukocyte sharing between the graft and the recipient so that the graft becomes a genetic composite of both the donor and recipient. Chimerism enhances the host&#8217;s tolerance of the graft because the recipient does not recognize the donor organ as foreign. The first evidence of chimerism was observed in 1969 when female recipients of male livers developed entirely female Kupffer cell (liver macrophage) systems (as demonstrated by the Barr bodies in the macrophage). In 1992, the concept of immune cell sharing became clinically evident when it was discovered that leukocytes from donor kidneys occupied remote lymph nodes.<br />
<strong></p>
<blockquote><p>16. Do resident macrophages exist in the heart and lungs? 	</strong></p></blockquote>
<p>Show answer<br />
Absolutely yes. Resident myocardial macrophages and resident alveolar macrophages are incredibly active cellular components of the heart and lungs.</p>
<blockquote><p><strong>17. Does chimerism develop in the heart and the lungs? </strong>	</p></blockquote>
<p>Show answer<br />
Yes. Because the heart and lungs each have leukocytes to share, they participate in chimerism.</p>
<blockquote><p><strong>18. Why is chimerism exciting?</strong> </p></blockquote>
<p>	Show answer<br />
Nature is trying to teach us how to perform transplantation without the use of immunosuppression. Our job is to learn why chimerism is induced in some recipients and not in others. That is, we should dissect the mechanisms of chimerism induction so that we may therapeutically induce chimerism in all recipients.</p>
<blockquote><p><strong>19. What are the major types of preservation solutions for heart and lung grafts? </strong>	</p></blockquote>
<p>Show answer<br />
Euro-Collins (EC) solution and University of Wisconsin (UW) solution for lung and crystalloid cardioplegia and UW solution for hearts.</p>
<blockquote><p><strong>20. What percentage of pulmonary blood flow goes to the transplanted lung after single-lung transplant? 	</strong></p></blockquote>
<p>Show answer<br />
Predictably, almost all of the pulmonary blood flow passes through the lower resistance circuit of the transplanted lung (depending on the pulmonary vascular resistance of the contralateral native-i.e., sick-lung). If a preoperative perfusion scan exists, other factors being equal, the lung with the best perfusion is preserved and the bad lung is replaced.<br />
<em><strong>KEY POINTS: LUNG TRANSPLANTATION</strong></p>
<p>   1. The most common indication for single lung transplant is emphysema.<br />
   2. The most common indication for double lung transplant is cystic fibrosis.<br />
   3. Chimerism is leukocyte sharing between the graft and the recipient so that the graft becomes a genetic composite of both donor and recipient.<br />
   4. Bronchiolitis obliterans, a major cause of long-term morbidity after lung transplantation, is a process in which membranous and respiratory bronchioles demonstrate histologic evidence of subepithelial scarring that eventually progresses to occlusion of the bronchiolar lumen.</em></p>
<blockquote><p><strong>21. Is cardiopulmonary bypass required for lung transplantation? </strong>	</p></blockquote>
<p>Show answer<br />
No. However, for patients with pulmonary hypertension (primary or secondary), cardiopulmonary bypass is routinely used before removal of the recipient&#8217;s lung. Cardiopulmonary bypass is always on standby. This is tricky anesthesia. One lung is transiently excised from a patient who is living (barely) on two bad lungs.</p>
<blockquote><p><strong>22. Is living-related lung transplant possible? </strong>	</p></blockquote>
<p>Show answer<br />
Yes. Living-related lung transplants are an innovative approach to increasing the donor pool. Typically, only one lobe from the donor is used to replace a whole lung in the recipient.</p>
<blockquote><p><strong>23. What is lung volume reduction surgery? How may it be important to patients on the lung transplant waiting list?</strong> </p></blockquote>
<p>	Show answer </p>
<p>Lung volume reduction surgery offers a therapeutic option for patients who are either not candidates to receive a lung transplant or on a long waiting list. Lung volume reduction surgery removes nonfunctional or destroyed lung. Removal of defunctionalized lung makes more room for airflow in the functional lung, thereby decompressing the distended chest.</p>
<blockquote><p><strong>24. Who is the best candidate for lung volume reduction surgery? 	</strong></p></blockquote>
<p>Show answer<br />
The best candidates are patients without contraindication who have absent or reduced perfusion of approximately one third of the lung (usually caused by a big cyst or emphysematous region), with good flow distribution in the remainder of the lung. Thus, quantitative lung perfusion scans provide essential information for patient selection.</p>
<blockquote><p><strong>25. What are the contraindications to lung reduction surgery?</strong></p></blockquote>
<p> 	Show answer </p>
<p>    * Pulmonary hypertension (mean pulmonary artery pressure [PAP] > 35 mmHg or systolic PAP > 45 mmHg)<br />
    * Significant coronary artery disease<br />
    * Previous thoracotomy or pleurodesis (visceral and parietal pleural fusion)<br />
    * Long-standing history of asthma, bronchiectasis, or chronic bronchitis with purulent sputum<br />
    * Severe kyphoscoliosis</p>
<blockquote><p>
<strong>26. What is the most common nonbacterial cause of pneumonia in lung transplant patients? 	</strong></p></blockquote>
<p>Show answer<br />
Cytomegalovirus (CMV), usually occurring 4-8 weeks postoperatively. Primary CMV infection usually results in more serious illness than reactivation disease. CMV-seronegative recipients should receive only blood products that are serologically negative.</p>
<blockquote><p><strong>27. In addition to immune suppressive therapy, what other factors put transplanted lungs at risk for infection?</strong> </p></blockquote>
<p>	Show answer<br />
Lung denervation, interruption of lymphatic clearance and bronchial circulation, and impaired mucociliary clearance.</p>
<blockquote><p><strong>28. What are the main differences in composition between EC and UW solutions? </strong>	</p></blockquote>
<p>Show answer<br />
EC solution is a glucose-based solution with an ionic composition that approximates that of the intracellular environment.<br />
UW solution does not contain glucose but does contain the following components not found in EC solution: hydroxy-ethyl starch (prevents expansion of the interstitial space), lactobionate and raffinose (suppress hypothermia-induced cell swelling), glutathione and allopurinol (reduce cytotoxic injury from oxygen free radicals), and adenosine (substrate for adenosine triphosphate formation, vasodilation, and activation of the protective mechanisms of &#8220;protective preconditioning&#8221;).</p>
<blockquote><p><strong>29. How many lung transplants are performed annually? Is the number increasing or decreasing? 	</strong></p></blockquote>
<p>Show answer<br />
Of interest, although the first human lung transplant was performed in 1963, significant numbers were not performed until the late 1980s (in 1986, 1 lung transplant; in 1989, 132 lung transplants). This number rapidly increased to 700 per year in 1994 and has since declined to approximately 625 per year worldwide.</p>
<blockquote><p><strong>30. Are the survival rates different for single- and double-lung transplants?</strong> </p></blockquote>
<p>	Show answer<br />
No. The 3-year actuarial survival rate is about 50% for each.</p>
<blockquote><p><strong>31. What are the 1-year, 2-year, and 3-year actuarial survival rates for single-lung retransplants? </strong>	</p></blockquote>
<p>Show answer<br />
Actuarial survival rates are 45%, 40%, and 30%, respectively. Predictably, such patients do significantly worse.</p>
<p><strong>References</strong><br />
WEB SITE<br />
<a href="http://www.transplantation-soc.org/">http://www.transplantation-soc.org</a><br />
BIBLIOGRAPHY<br />
1. Baumgartner WA: Myocardial and pulmonary protection: Long-distance transport. Prog Cardiovasc Dis 33:85-96, 1990. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=2203111&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=2203111">Similar articles</a><br />
2. Christie JD, Bavaria JE, Palevsky HI, et al: Primary graft failure following lung transplantation. Chest 114:51-60, 1998.<br />
3. Cooper JD, Patterson GA: Lung transplantation. In Sabiston D, Spencer F (eds): Surgery of the Chest, 7th ed. Philadelphia, W.B. Saunders, 1995, pp 2117-2134.<br />
4. Gaynor JW, Bridges ND, Clark BJ, et al: Update on lung transplantation in children. Curr Opin Pediatr 10:256-261, 1998.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9716886&#038;dopt=Abstract"> Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9716886">Similar articles</a><br />
5. Hosenpud JD, Bennett LE, Keck BM, et al: The Registry of the International Society for Heart and Lung Transplantation: Eighteenth official report-2001. J Heart Lung Transplant 20:805-815, 2001.<br />
6. Keller CA: The donor lung: Conservation of a precious resource. Thorax 53:506-513, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9713453&#038;dopt=Abstract">Medline </a>S<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9713453">imilar articles</a><br />
7. Meyers BF, Patterson GA: Technical aspects of adult lung transplantation. Semin Thorac Cardiovasc Surg 10:213-220, 1998.<br />
8. Nunley DR, Grgurich W, Iacono AT, et al: Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 113:1235-1243, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9596300&#038;dopt=Abstract">Medline </a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9596300">Similar articles</a><br />
9. Rich S, McLaughlin VV: Lung transplantation for pulmonary hypertension: Patient selection and maintenance therapy while awaiting transplantation. Semin Thorac Cardiovasc Surg 10:135-138, 1998.<br />
10. Sundaresan S: The impact of bronchiolitis obliterans on late morbidity and mortality after single and bilateral lung transplantation for pulmonary hypertension. Semin Thorac Cardiovasc Surg 10:152-159, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9620464&#038;dopt=Abstract">Medline</a> S<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9620464">imilar articles</a><br />
11. Waddell TK, Keshavjee S: Lung transplantation for chronic obstructive pulmonary disease. Semin Thorac Cardiovasc Surg 10:191-201, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9717908">Similar articles</a><br />
12. Zenati M, Keenan RJ, Courcoulas AP, et al: Lung volume reduction or lung transplanation for end-stage pulmonary emphysema? Eur J Cardiothorac Surg 14:27-31, 1998.</p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/transplantation/lung-transplantation/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Liver Transplantation</title>
		<link>http://surgeryprocedure.info/transplantation/liver-transplantation</link>
		<comments>http://surgeryprocedure.info/transplantation/liver-transplantation#comments</comments>
		<pubDate>Mon, 13 Jul 2009 18:48:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRANSPLANTATION]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=444</guid>
		<description><![CDATA[89 LIVER TRANSPLANTATION
Thomas E. Bak M.D., Michael E. Wachs M.D., Igal Kam M.D.
1. When and where was the first liver transplant performed?
 	Show answer
Dr. Thomas Starzl performed the first operation on March 1, 1963, at the University of Colorado in Denver.
2. Is liver transplantation considered a safe and effective operation? 
	Show answer
Yes. Although still a [...]]]></description>
			<content:encoded><![CDATA[<p><strong>89 LIVER TRANSPLANTATION<br />
Thomas E. Bak M.D., Michael E. Wachs M.D., Igal Kam M.D.</strong></p>
<blockquote><p><strong>1. When and where was the first liver transplant performed?</strong></p></blockquote>
<p> 	Show answer<br />
Dr. Thomas Starzl performed the first operation on March 1, 1963, at the University of Colorado in Denver.</p>
<blockquote><p><strong>2. Is liver transplantation considered a safe and effective operation?</strong> </p></blockquote>
<p>	Show answer<br />
Yes. Although still a major operation with significant risks, patient and graft survival have continuously improved. One-year survival should be well over 90% in major centers.</p>
<blockquote><p><strong>3. What are the most common indications for liver transplantation in the United States? </strong>	</p></blockquote>
<p><span id="more-444"></span><br />
Show answer<br />
Noncholestatic cirrhosis characterizes > 50% of the recipients. This group includes those with viral hepatitis, alcoholic cirrhosis (Laennec&#8217;s), and Budd-Chiari syndrome. Cholestatic cirrhosis makes up an additional 15%, with primary sclerosing cholangitis (PSC) and primary biliary cirrhosis heading this group. Other indications include biliary atresia, acute hepatic necrosis, malignant neoplasms, and metabolic disease.</p>
<blockquote><p><strong>4. Has the most common disease requiring transplantation shifted over the years? 	</strong></p></blockquote>
<p>Show answer<br />
Yes. The largest percentage of people now being transplanted have hepatitis C. There are also more retransplants performed because some diseases such as hepatits C and PSC can recur in transplanted livers.</p>
<blockquote><p><strong>5. How is the waiting list run? </strong>	</p></blockquote>
<p>Show answer<br />
Changes have been made to the list so that the sickest patients get transplanted first. New scoring systems (Mayo End-stage Liver Disease [MELD] score) have been devised to give more weight to objective markers of illness rather than the more subjective medical criteria used in the past. This point system has also minimized the importance of time spent on the waiting list. The goal of these changes is to reduce waiting list mortality.</p>
<blockquote><p><strong>6. What are some of the recent advances in liver transplant surgery? </strong>	</p></blockquote>
<p>Show answer<br />
Operative techniques have improved such that some liver transplant recipients do not require a stay in the intensive care unit, venovenous bypass, or external biliary drainage, and operative times are shorter (4-5 hours). Improved immunosuppression medications have reduced rejection rates and side effects.</p>
<blockquote><p><strong>7. How long can a liver be kept &#8220;on ice&#8221;? </strong>	</p></blockquote>
<p>Show answer<br />
Optimal cold ischemia should be < 12 hours.</p>
<blockquote><p><strong>8. What are some common postoperative complications of liver transplantation? </strong>	</p></blockquote>
<p>Show answer<br />
Postoperative bleeding, infection, and biliary complications are the most common. Primary nonfunction (< 5%) and early hepatic artery thrombosis (5%) are less common, but they usually require an urgent retransplant.</p>
<blockquote><p><strong>9. What is the &#8220;piggy-back&#8221; technique? 	</strong></p></blockquote>
<p>Show answer<br />
This is a technique in which the recipient&#8217;s sick liver is carefully resected off of his or her vena cava, which is left in situ. The upper donor cava is then sewn to a common cuff of native hepatic veins. The donor&#8217;s lower cava is ligated. Using this method, it is possible to do the complete transplant with minimal if any vena caval occlusion, resulting in less intraoperative hemodynamic instability.</p>
<blockquote><p><strong>10. Is living-donor liver transplantation an option?</strong> 	</p></blockquote>
<p>Show answer<br />
Yes. Initially used in the pediatric population using an adult left lateral segment graft, this procedure has evolved into fairly common practice. The Far East has had a large number of adult-to-adult left lobe graft series. Elsewhere, this has been replaced with a right lobe donor operation. Both the donor and recipient liver lobes quickly regenerate to normal size. Results in experienced centers mimic those of cadaveric transplant with similar patient survival, albeit at higher complication and retransplant rates.<br />
<em><strong>KEY POINTS: LIVER TRANSPLANTATION<br />
</strong><br />
   1. The most common indication for liver transplantation in the United States is noncholestatic cirrhosis.<br />
   2. Optimal cold ischemia time for the liver is < 12 hours.<br />
   3. Transjugular intrahepatic portosystemic shunts can be used in potential transplant recipients as a bridge to transplantation.<br />
</em></p>
<blockquote><p><strong>11. How have transjugular intrahepatic portosystemic shunts (TIPS) improved this field of surgery?</strong> </p></blockquote>
<p>	Show answer<br />
TIPS can be used in potential transplant recipients as a bridge to transplantation. This procedure is very effective in controlling portal hypertension without the need for a major abdominal operative shunt. A prior portocaval shunt does complicate a liver transplant, but it is not a contraindication to liver transplantation.</p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/transplantation/liver-transplantation/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kidney &amp; Pancreas Transplantation</title>
		<link>http://surgeryprocedure.info/transplantation/kidney-pancreas-transplantation</link>
		<comments>http://surgeryprocedure.info/transplantation/kidney-pancreas-transplantation#comments</comments>
		<pubDate>Mon, 13 Jul 2009 19:12:52 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRANSPLANTATION]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=452</guid>
		<description><![CDATA[90 KIDNEY AND PANCREAS TRANSPLANTATION
Thomas E. Bak M.D., Michael E. Wachs M.D., Igal Kam M.D.
1. What are the most common indications for kidney transplantation? 

	Show answer
End-stage renal disease (ESRD) caused by hypertension, diabetes, glomerulonephritis, and polycystic kidney disease.

2. Why should patients be taken off dialysis and have kidney transplants?
 	Show answer
Although not a life-saving transplant [...]]]></description>
			<content:encoded><![CDATA[<p><strong>90 KIDNEY AND PANCREAS TRANSPLANTATION<br />
Thomas E. Bak M.D., Michael E. Wachs M.D., Igal Kam M.D.</strong></p>
<blockquote><p><strong>1. What are the most common indications for kidney transplantation? </strong></p></blockquote>
<blockquote><p>
	Show answer<br />
End-stage renal disease (ESRD) caused by hypertension, diabetes, glomerulonephritis, and polycystic kidney disease.</p>
<p><span id="more-452"></span></p>
<blockquote><p><strong>2. Why should patients be taken off dialysis and have kidney transplants?</strong></p></blockquote>
<p> 	Show answer<br />
Although not a life-saving transplant like liver or heart transplantation, kidney transplantation will improve patients&#8217; quality of life. Patient 5-year survival is higher posttransplant when compared with continued dialysis. Finally, there is a cost savings with kidney transplantation compared with long-term dialysis.</p>
<blockquote><p><strong>3. How long is kidney graft survival? </strong></p></blockquote>
<p>	Show answer<br />
Cadaveric kidney transplant survival rates have steadily improved over the years. Currently, 1-year graft survival is 90%, with a 10-year graft survival of > 50%.</p>
<blockquote><p><strong>4. How long can kidneys be kept &#8220;on ice&#8221;? </strong>	</p></blockquote>
<p>Show answer<br />
Kidneys can survive and function after longer cold ischemia time than other solid organs. Function can be maintained up to 72 hours, although optimal function is achieved if cold ischemia is kept under 24 hours. Patients on the waiting list frequently continue to work and travel and still have plenty of time to get to the hospital for tranplant. Also, United Network of Organ Sharing (UNOS) kidneys are frequently sent via commercial airlines all across the country.</p>
<blockquote><p><strong>5. Where is the transplanted kidney placed?</strong> </p></blockquote>
<p>	Show answer<br />
Most commonly, the kidney is placed in the right iliac fossa. The peritoneal cavity is reflected superiorly, and the external iliac vessels are exposed. The renal artery and vein are then anastomosed end-to-side to the iliac vessels.</p>
<blockquote><p><strong>6. What are the indications for nephrectomy?</strong></p></blockquote>
<p> 	Show answer<br />
Indications for nephrectomy include chronic infection, symptomatic polycystic kidney disease, intractable hypertension, and heavy proteinurea. The majority of transplant recipients do not need to undergo native nephrectomies.</p>
<blockquote><p><strong>7. Are living-donor kidney transplants recommended?</strong> </p></blockquote>
<p>	Show answer<br />
There are definite advantages to receiving a living-donor kidney. The average survival times of these kidneys are significantly better. Also, the long cadaveric kidney waiting time (usually measured in years) can be avoided. Donors are carefully screened to ensure health and lack of any coercion.</p>
<blockquote><p><strong>8. Is donating a kidney a major operation for living donors?</strong></p></blockquote>
<p> 	Show answer<br />
The standard of care for donor operations has become a laparoscopic donor nephrectomy. This technique has proven to be safe, with no negative effects on the kidney. The benefits of this modification over the open technique are much quicker recovery and shorter return-to-work time. This has generally increased the number of people interested in being living donors.</p>
<blockquote><p><strong>9. What are the indications for kidney-pancreas (K-P) transplantation? 	</strong></p></blockquote>
<p>Show answer<br />
In general, all type 1 diabetics who have poorly controlled diabetes despite optimal medical management should be considered for K-P transplantation as long as they are acceptable surgical risks. Unfortunately, many older patients have significant, even prohibitive, comorbidities. A pancreas transplant adds significant morbidity and mortality risks over a kidney-only transplant.</p>
<blockquote><p><strong>10. Can a patient undergo pancreas transplantation before or after a kidney transplant? </strong>	</p></blockquote>
<p>Show answer<br />
Yes. Patients can receive a simultaneous K-P transplant. This is the most common course, and the operation is done through a midline abdominal incision with the pancreas and kidney placed on opposite iliac vessels. Patients can also receive a pancreas-only transplant or pancreas-after-kidney transplant. The survival for these grafts is similar. Some centers are now shifting to portal drainage of the pancreas, with the venous outflow established to the superior mesenteric vein.<br />
<em><strong>KEY POINTS: KIDNEY AND PANCREAS TRANSPLANTATION</strong></p>
<p>   1. The most common indication for kidney transplantation is end-stage renal disease caused by hypertension, diabetes, glomerulonephritis, and polycystic kidney disease.<br />
   2. Cadaveric kidney transplant survival rates have steadily improved over the years, with current 1-year graft survival rates of 90% and a 10-year graft survival rate of > 50%.<br />
   3. In general, all type 1 diabetics with poorly controlled diabetes despite optimal medical management should be considered for kidney-pancreas transplantation as long as they are acceptable surgical risks.</em></p>
<blockquote><p><strong>11. How are digestive enzymes drained in a pancreas transplant? </strong></p></blockquote>
<p>	Show answer<br />
The donor pancreas is procured with a duodenal cuff still attached, with enzymatic drainage from the graft into this cuff intact. The duodenal cuff is then drained into a piece of recipient&#8217;s small intestine with an enteric anastomosis. An alternative is to attach the duodenal cuff to the bladder. This allows amylase levels to be followed in the urine, but metabolic and infectious complications frequently require a conversion to enteric drainage.</p>
<blockquote><p><strong>12. What are some complications commonly seen with pancreas transplant? </strong>	</p></blockquote>
<p>Show answer<br />
Leakage from the duodenal cuff, graft venous thrombosis, infection, rejection, and graft pancreatitis are all potential complications. The incidence of these is decreasing as more experience is gained, and pancreas graft survival now approaches kidney graft survival.</p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/transplantation/kidney-pancreas-transplantation/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Splenic Trauma</title>
		<link>http://surgeryprocedure.info/trauma/splenic-trauma</link>
		<comments>http://surgeryprocedure.info/trauma/splenic-trauma#comments</comments>
		<pubDate>Tue, 07 Jul 2009 21:00:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[TRAUMA]]></category>

		<guid isPermaLink="false">http://surgeryprocedure.info/?p=162</guid>
		<description><![CDATA[26 SPLENIC TRAUMA
David J. Ciesla M.D., Ernest E. Moore M.D.
1. What is the physiologic role of the spleen? 	
Show answer
In fetal development, the spleen serves as a major site for hematopoiesis. In early childhood the spleen produces immunoglobulin M (IgM) and tuftsin. The spleen also functions as a filter, allowing resident macrophages to remove abnormal [...]]]></description>
			<content:encoded><![CDATA[<p><strong>26 SPLENIC TRAUMA<br />
David J. Ciesla M.D., Ernest E. Moore M.D.</strong></p>
<blockquote><p><strong>1. What is the physiologic role of the spleen?</strong> 	</p></blockquote>
<p>Show answer<br />
In fetal development, the spleen serves as a major site for hematopoiesis. In early childhood the spleen produces immunoglobulin M (IgM) and tuftsin. The spleen also functions as a filter, allowing resident macrophages to remove abnormal red blood cells (RBCs), cellular debris, and encapsulated and poorly opsonized bacteria.</p>
<p><span id="more-162"></span></p>
<blockquote><p><strong>2. What injury patterns are associated with splenic trauma?</strong> </p></blockquote>
<p>	Show answer<br />
Direct blunt force, deceleration, and compression to the left torso. Think spleen after a motor vehicle accident or fall: lower rib fractures, left side-only rib fractures, and high-energy transfer (big hits) increase the probability of splenic injury.</p>
<blockquote><p><strong>3. What are the signs and symptoms of splenic injury?</strong></p></blockquote>
<p> 	Show answer<br />
The main sign is pain in the left upper quadrant. This is produced by stretching the splenic capsule. Peritoneal irritation (rebound tenderness) is caused by extravasated blood (blood is very irritating). Vital signs vary depending on associated blood loss and are not specific for injuries to the spleen. Unfortunately, a large number of patients with a significant splenic injury exhibit no signs or symptoms at all.</p>
<blockquote><p><strong>4. What studies can help in diagnosing splenic trauma? </strong>	</p></blockquote>
<p>Show answer<br />
Ultrasound (US) can be performed in the emergency department and can rapidly identify as little as 200 mL fluid/blood. When US is not available, diagnostic peritoneal lavage (DPL) is an accurate and sensitive measure of intraabdominal bleeding.<br />
Hemodynamically stable patients permit more thorough evaluations. Although US is extremely sensitive for detecting intraabdominal bleeding, computed tomography (CT) not only can detect and quantify intraabdominal blood but also can characterize specific intraabdominal injuries.</p>
<blockquote><p><strong>5. How are splenic injuries classified, and why is that important?</strong> </p></blockquote>
<p>	Show answer<br />
Management is governed by the hemodynamic status of the patient, but therapy is also influenced by the CT grade of splenic injury. Nonoperative management is most successful in grades I-III, whereas operative intervention is often required for grade IV injuries. Grade V injuries demand prompt operative intervention. (See Table 26-1.)</p>
<blockquote><p><strong>6. Do splenic injuries require laparotomy?</strong> 	</p></blockquote>
<p>Show answer<br />
No. Nonoperative management is successful in approximately 95% of patients with grades I-III. Hemodynamically stable patients with evidence of ongoing bleeding (requiring transfusion) may be treated by selective arterial embolization if a bleeding site is identified on angiography.</p>
<blockquote><p><strong>7. What are contraindications to nonoperative management of splenic injuries?</strong> 	</p></blockquote>
<p>Show answer </p>
<p>    * Hemodynamic instability<br />
    * Persistent coagulopathy<br />
    * Additional intraabdominal injury requiring operative intervention<br />
<strong>. GRADES OF SPLENIC INJURY</strong></p>
<table width="100%" border=1 cellpadding=2 bordercolor="#c0c0c0" cellspacing=2 bgcolor="#ffffff">
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div><b>Grade</b></div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div><b>Description</b></div>
<p></font>
</td>
</tr>
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div>I</div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div>Hematoma: nonexpanding subcapsular &lt; 10% surface area</div>
<div>Laceration: nonbleeding capsular &lt; 1 cm parenchymal depth</div>
<p></font>
</td>
</tr>
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div>II</div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div>Hematoma: nonexpanding, subcapsular &lt; 50% surface area</div>
<div>Nonexpanding intraparenchymal &lt; 5 cm diameter</div>
<div>Laceration: bleeding, capsular &lt; 3 cm parenchymal depth</div>
<p></font>
</td>
</tr>
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div>III</div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div>Hematoma: subcapsular &gt; 50% surface area, expanding, ruptured with active bleeding</div>
<div>Intraparenchymal &gt; 5 cm diameter or expanding</div>
<div>Laceration: capsular &gt; 3 cm parenchymal depth, involving trabecular vessel</div>
<p></font>
</td>
</tr>
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div>IV</div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div>Hematoma: ruptured, intraparenchymal, with active bleeding</div>
<div>Laceration: involves segmental or hilar vessels with &gt; 25% splenic devascularization</div>
<p></font>
</td>
</tr>
<tr valign=top>
<td width=66><font size=2 color="#000000" face="Arial"></p>
<div>V</div>
<p></font>
</td>
<td width=459><font size=2 color="#000000" face="Arial"></p>
<div>Laceration: shattered spleen</div>
<div>Vascular: hilar avulsion or complete splenic devascularization</div>
<p></font>
</td>
</tr>
</table>
<blockquote><p><strong>8. What is the failure rate of nonoperative management of splenic injury? </strong></p></blockquote>
<p> 	Show answer<br />
Any patient with signs of hemodynamic instability, persistent bleeding, worsening pain or tenderness, or progressive injury by CT scanning has failed nonoperative management. Approximately 60% of all splenic injuries can be managed nonoperatively with a failure rate of 12%. Factors that predict nonoperative failure include multiple injuries, grade III-V spleen injuries, age > 55 years, and blood traunsfusion.<br />
<em><strong>KEY POINTS: EXPECTANT MANAGEMENT OF SPLENIC INJURIES</strong></p>
<p>   1. Nonoperative management is successful in 95% of grades I-III injuries.<br />
   2. 60% of all splenic injuries are managed nonoperatively, with a 12% failure/conversion rate.<br />
   3. Factors that predict failure/conversion to operative treatment include injury > grade III, age > 55 years, and blood transfusion requirements.<br />
   4. Patients with evidence of ongoing bleeding (e.g., contrast &#8220;blush&#8221; on CT or ongoing transfusion requirements) may be managed with selective arterial embolization.</em></p>
<blockquote><p><strong>9. What is delayed rupture of the spleen?</strong></p></blockquote>
<p> 	Show answer<br />
This is a rare complication that occurs in < 1% of patients with a splenic injury. Delayed splenic rupture should be distinguished from a delay in diagnosis of splenic injury and rupture of a known splenic injury. True delayed splenic rupture occurs > 48 hours in a patient with a history of abdominal trauma and no overt clinical evidence of intraabdominal injury on initial presentation.</p>
<blockquote><p><strong>10. What are the general principles of operative management of the injured spleen? </strong>	</p></blockquote>
<p>Show answer<br />
The first priority is to control bleeding. This can usually be accomplished by packing and manual compression of the spleen. If successful, the abdomen is then thoroughly explored for other injuries. Complete mobilization of the spleen by division of the splenocolic, splenorenal, phrenosplenic, and gastrosplenic ligaments is required for complete assessment of the spleen. The short gastric vessels can be ligated with division of the gastrosplenic ligament. Repair of the spleen can be accomplished by application of hemostatic agents, direct pledgeted suture repair of the splenic parenchyma, partial splenectomy, and construction of a &#8220;splenic wrap&#8221; using absorbable mesh. If splenectomy is required, the splenic artery and vein should be ligated individually prior to removing the spleen.</p>
<blockquote><p><strong>11. What early complications arise after splenectomy? </strong>	</p></blockquote>
<p>Show answer<br />
Bleeding, acute gastric dilatation, gastric perforation, pancreatitis (the splenic artery courses along the top of the pancreas), and subphrenic abscess.</p>
<blockquote><p><strong>12. What is splenic autotransplantation? </strong>	</p></blockquote>
<p>Show answer<br />
Autotransplantation is accomplished by implanting splenic tissue parenchymal slices into pouches created in the gastrocolic omentum.</p>
<blockquote><p><strong>13. Does splenic autotransplantation preserve splenic function? 	</strong></p></blockquote>
<p>Show answer<br />
Autotransplantion after splenectomy is controversial. At least 30% of the original splenic mass is needed to provide normal function. After autotransplantation, IgG and IgM levels are increased in response to pneumococcal vaccine compared with patients after splenectomy alone.</p>
<blockquote><p><strong>14. Does postsplenectomy leukocytosis predict infection?</strong> 	</p></blockquote>
<p>Show answer<br />
Elevations in white blood cell (WBC) count and platelet count (PC) after splenectomy are a common physiologic event. After the fourth postoperative day, however, a WBC > 15 x 103 and a PC/WBC < 20 are highly associated with sepsis and should not be confused with the physiologic response to splenectomy.</p>
<blockquote><p><strong>15. Should a follow-up CT scan be performed after nonoperative management of splenic injuries before patient discharge? 	</strong></p></blockquote>
<p>Show answer<br />
No. Most patients who fail nonoperative management do so within 5 days and will exhibit hemodynamic evidence of ongoing hemorrhage. However, follow-up CT should be performed for grade III and IV injuries at 4-6 weeks before getting back to vigorous physical activity.</p>
<blockquote><p><strong>16. What is OPSS, and how is it prevented? </strong>	</p></blockquote>
<p>Show answer<br />
Overwhelming post splenectomy sepsis (OPSS) is a devastating bacteremia (typically encapsulated bacteria) that occurs in 2% of patients after splenectomy. The risk of OPSS is greatest when splenectomy is performed during infancy. The most common organisms are pneumococcus (50%), meningococcus, Escherichia coli, Haemophilus influenzae, staphylococcus, and streptococcus. Although rare, OPSS carries a mortality rate of 75% and has spurred interest in splenic preservation. OPSS is primarily prevented by postoperative vaccination. Pneumococcal, meningococcal, and Haemophilus flu vaccines should be given 2 weeks after splenectomy and are recommended every 5 years. Sepsis can occur despite vaccination; consequently, long-term prophylaxis with oral penicillin is recommended for children.</p>
<p><strong>References</strong><br />
WEB SITES</p>
<p>   <a href="http://www.east.org/tpg/bluntabd.pdf">1. http://www.east.org/tpg/bluntabd.pdf</a><br />
   <a href="http://www.acssurgery.com/abstracts/acs/acs0506.htm">2. http://www.acssurgery.com/abstracts/acs/acs0506.htm</a></p>
<p>BIBLIOGRAPHY<br />
1. Cocanour CS, Moore FA, Ware DN, et al: Delayed complications of nonoperative management of blunt adult splenic trauma. Arch Surg 133:619-624, 1998. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=9637460&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=9637460">Similar articles</a> <a href="http://dx.doi.org/10.1001/archsurg.133.6.619">Full article</a><br />
2. Leemans R, Manson W, Snijder JA, et al: Immune response capacity after human splenic autotransplantation: Restoration of response to individual pneumococcal vaccine subtypes. Ann Surg 229:279-285, 1999. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=10024111&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=10024111">Similar articles</a><a href="http://dx.doi.org/10.1097/00000658-199902000-00017"> Full article</a><br />
3. Moore EE, Cogbill TH, Jurkovich GJ, et al: Organ injury scaling: Spleen and liver (1994 revision). J Trauma 38:323-324, 1995.<br />
4. Shatz DV: Vaccination practices among North American trauma surgeons in splenectomy for trauma. J Trauma 53:950-956, 2002.<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=12435949&#038;dopt=Abstract"> Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=12435949">Similar articles</a> <a href="http://dx.doi.org/10.1097/00005373-200211000-00023">Full article</a><br />
5. Toutouzas KG, Velmahos GC, Kaminski A, et al: Leukocytosis after posttraumatic splenectomy: A physiologic event or sign of sepsis? Arch Surg 137:924-928, 2002. <a href="http://dx.doi.org/10.1097/00005373-200211000-00023">Full article</a><br />
6. Uecker J, Pickett C, Dunn E: The role of follow-up radiographic studies in nonoperative management of spleen trauma. Am Surg 67:22-25, 2001. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#038;db=PubMed&#038;list_uids=11206890&#038;dopt=Abstract">Medline</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&#038;cmd=Display&#038;dopt=pubmed_pubmed&#038;from_uid=11206890">Similar articles</a></p>
]]></content:encoded>
			<wfw:commentRss>http://surgeryprocedure.info/trauma/splenic-trauma/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
